WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS 11th Annual Conference Guide www.sachsforum.com 13th-14th September 2011 13th-14th September INVESTOR FORUM INVESTOR

Hilton Zurich Airport Hotel, Switzerland Hotel, Hilton Zurich Airport BIOTECH IN EUROPE IN BIOTECH M U R O F R O T S E V N I E P O R U E N I H C E T O I B WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS next u General Information The registration be open from 8am on September 13th and from 8.15am on September desk will Please collect a copy of the agenda for 14th although you are welcome to join the event at any time. information room allocation on timing and for each session. which is available to Networking at the Forum is facilitated by our online 1-2-1 meeting system, all participants. A & B rooms. A Networking Lunch will be set up in the Zurich A & B rooms and the presentation the rooms throughout Coffee stations up in the Zurich will be set event. Sachs Associates are delighted to welcome you to the 11th Annual Biotech in Europe Investor Annual Associates to welcome you to the 11th are delighted Sachs the forum again once provides access to an Following the success of previous years, Forum. small-capexciting cross-section of venture-funded and and companies with leading investors pharmas. This Forum is highly transactional and is comprised of a series of panels and presentations each one providing an expert pharmaceutical and biotech companies, from leading investment, industry. Biotech outlook on growth and investment activity in Europe’s the Private The programme highlights the current issues surrounding the evolving M&A market, Plus, Capital major trends in Partnering. environment and a special session on Venture Equity & programme features more than 70 company presentations from a range of publicly this year’s listed and private life science companies looking to raise finance and/or find partners. Sachs Associates are delighted to welcome you to the: are delighted to welcome you to Sachs Associates Annual 11th in Europe Biotech Forum Investor 13th-14th September 2011 Switzerland Hotel, Airport Hilton Zurich Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request will endeavour to send you the requested We to [email protected] after the conference. presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides thatconference. are shown during the Welcome WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back For regular updates, sponsorship, presenting and attending opportunities presenting and attending opportunities sponsorship, For regular updates, regarding anyand further information future events please contact of our Zoe Harris on [email protected] 5th Annual European Life Science CEO Forum 5th Annual European & Investing For Partnering 28 – 29 FebruaryZurich • Switzerland 2012 • and highly this exclusive transactional partnering event is a must for companies Back for year, its fifth engage with leading investors and forge partnerships. new wishing to meet with their peers, the forum will provide an excellent platform to gain event, Building on the success of this year’s Networking at the in the Biotech and Pharma industry. insight into partnering and investment trends which is available to all participants. Forum is facilitated by our online 1-2-1 meeting system, The conference will feature up to 8 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners. leading global investors and Do not miss out on this great opportunity to meet emerging companies, Big Pharma representatives! Events Diary Events WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u www.glsv-vc.com Investing in the life sciences independent venture capital fund focusing exclusively on is a leading, (GLSV) Ventures Global Life Science scientific originating from universities, is dedicated GLSV to supporting early-stage groups, the life sciences. For this including buy-outs. The fund may also invest in selected later stage companies, institutions or industry. The group currently and advises networks. advice and access to expertise and finance, GLSV provides purpose, GLSV acts as one With offices in Germany Switzerland, and manages funds totalling more than € 200 million. team with a global perspective. www.glsv-vc.com please see our website: For more information, GmbH Ventures Global Life Science 3 Von-der-Tann-Str. D - 80539 München Germany Phone +49 (0)89 - 288 151-0 Fax +49 (0)89 - 288 151-30 Sponsors Global Life Science Ventures Global Life WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u www.nyx.com NYSE Euronext (NYX) is a leading global operatorNYSE Euronext (NYX) is a of financial markets and provider of innovative trading fixed- options, futures, exchanges in Europe and the United States trade equities, company’s The technologies. products. income and exchange-traded equities NYSE Euronext’s With approximately Products), 8,000 listed issues (excluding European Structured Arca – Alternext and NYSE NYSE Amex, NYSE NYSE Euronext, Stock Exchange, York markets – the New NYSE the most liquidity of any global exchange group. equities trading, represent one-third of the world’s second- one of the leading European derivatives the world’s businesses and Euronext also operates NYSE Liffe, The company offers comprehensive commercial technology, largest derivatives business by value of trading. NYSE Euronext is in the S&P Technologies. connectivity and market data products and services through NYSE and is the only exchange operator in the Fortune 500. 500 index, please visit: www.nyx.com For more information, NYSE Euronext Sponsors WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u www.ricerca.com Founded in 1986, Ricerca Biosciences offers a comprehensive suite of discovery, preclinical and development preclinical Biosciences offers Ricerca of discovery, a comprehensive suite Founded in 1986, Capabilities services drug candidates to support from lead identification through IND and NDA on a global scale. radiochemistry, chemistry, as well as medicinal in vivo screening and profiling, include molecular through Our API. API process chemistry of clinical and commercial and cGMP manufacturing IND-enabling toxicology, world-class expertise and servicesexperienced scientists deliver to IND and bring to help you shorten time molecules to the clinic faster. Ricerca also has ISO Washington, and Bothell, Ohio, In addition to U.S.-based facilities in Concord, Lyon facility also holds certification from the The France. Lyon, and Taiwan, Taipei, 9001-certified facilities in Animal Care (AAALAC). Accreditation of Laboratory Assessment and Association for Discovery Pharmacology Molecular profiling & screening Functional pharmacology Early cellular toxicology Cellular oncology and immune systems In vivo safety and disease models Discovery DMPK Chemical Development Medicinal chemistry Analytical chemistry Process chemistry Engineering and scale-up Radiosynthesis API production with cGMP controls Drug Safety and Metabolism General toxicology Safety pharmacology Continuous infusion Juvenile toxicology DART Bioanalytical services Ricerca Biosciences Auburn Road 7528 OH 44077 Concord, USA +1 888 RICERCA (742 3722) Tel: 440 354 6276 Fax: Ricerca Biosciences Sponsors ECM SPONSORS WELCOME

VC Partner

Merck Serono International SA www.serono.com VC PARTNER

Our active ingredient is Innovation At Merck Serono, we are actively committed to bringing therapeutic innovations to patients. We specialize in the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases and other conditions with unmet medical needs.

Around the world, over 17,000 employees work to discover, develop, manufacture and commercialize PRESENTING COMPANIES SPEAKERS Merck Serono’s prescription therapies, available in over 150 countries. We are internationally recognized as a biotechnology leader, with innovative and successful products along with a well-stocked and promising development pipeline. Specialized know-how in research and production means that we are able to ensure absolutely high-quality manufacturing, a key success factor especially in the biopharmaceutical industry. In 2007, sales of Merck Serono products generated total revenues of €4.5 billion. We devote 20% of these earnings to the pursuit of innovative new therapies through our own research and development, strategic alliances and agreement.

Merck Serono S.A. 9, chemin des Mines Case postale 54 CH-1211 Geneva 20 Switzerland Tel.: +41-22-414 3000 Fax: +41-22-414 2179 PARTNERING ORGANISATIONS EINLPRNR ORGANISERS REGIONAL PARTNERS ECM SPONSORS WELCOME

Speakers

Tim Haines, Partner, Abingworth LLP

Tim has more than 25 years of international management experience in the life sciences industry. Before joining Abingworth VC PARTNER in September 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for more than five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe. Current and past board positions include Astex Therapeutics, Fovea, IMI, KSpine, PowderMed, Stanmore Implants and XCounter. Tim has a BSc from Exeter University and an MBA from INSEAD. He is a former Director of the Biotechnology Industry Association and currently sits t back ::

on the Venture Committee of the BVCA. At Abingworth, he identifies and creates new businesses and provides support for SPEAKERS portfolio companies. next u Jason Avery, Head of Business Development, Affitech AS Jason is a highly experienced business development executive, specializing in the pharmaceutical/biotechnology sectors. From 2005 to 2007, Jason was the Founder and CEO of Funxional Therapeutics, raising venture capital from leading investors. Jason has also been the founder and CEO of a number of other small start-ups over the last 7 years. Jason was PRESENTING COMPANIES Chief Business Officer at Cambridge Antibody Technology from 1996 to 2003. At CAT, he he was a key member of the Executive Management Team, and was responsible for executing over 25 deals with pharmaceutical and biotechnology companies. Prior to CAT, Jason was with Ernst & Young for 11 years as a Director Corporate Finance & Consultancy, based in London and in Palo Alto near San Francisco. Jason graduated as a Civil & Structural Engineer, and has qualified as a Chartered Accountant in England. He is a Fellow of The Royal Institution, a member of the Institute of Directors, has a distinction from the Harvard Law School Program on Negotiation. Amongst Jason’s specialties are PR/IR, marketing, strategy, MBOs, M&A, business development, deal structuring, negotiation, competitive intelligence, & alliance management. Jason’s scientific expertise includes platform technology, antibodies, therapeutic proteins, small molecules, inflammatory diseases, oncology, cardiovascular diseases, fixed-dose combinations and bio-similars. Jason started with Affitech early in 2011. PARTNERING ORGANISATIONS

Katya Smirnyagina, Venture Partner, Alta Partners Katya Smirnyagina joined Alta in 2002 and focuses on European investment opportunities. She currently represents Alta on the board of directors of Cerenis Therapeutics and Kiadis Pharma. She also led Alta’s investment in Ablynx. Prior to joining Alta, she worked in business development and finance at Genset, a French genomics-based biotechnology company, where she negotiated a number of licensing agreements and strategic partnerships. Prior to Genset, Katya was a manager with the Mitchell Madison Group, a global management-consulting firm, from 1997 to 2000. She obtained a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and received her Bachelor of Science in Biochemistry with high honors from Moscow University in Russia. Katya completed her scientific training as a post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine. She has co-authored a number of scientific papers.

Hans Loibner, CEO, Apeiron Biologics AG ORGANISERS REGIONAL PARTNERS Hans Loibner has acted since 2005 as CEO of Apeiron Biologics AG, a product-oriented biotech company in Vienna, focusing on development of biologic / immunologic treatments of cancer (www.apeiron-biologics.com), with a pipeline of 5 clinical projects up to Phase III and several preclinical projects. In 2004, Loibner founded HL-Bioscience Research GmbH, a consulting company in Vienna specializing in cancer immunotherapy projects. In 1999, Loibner was founder of Igeneon, a cancer immunotherapy company focused on cancer vaccines and monoclonal antibodies, and acted as CEO until mid 2004. Loibner started his career at Sandoz/Novartis in 1977, stayed there until 1999 and held various R&D management positions. Since 1985 Loibner is engaged in commercially oriented cancer immunotherapy approaches and developed several projects up to Phase II/III clinical trials. Loibner holds a PhD from the University of Vienna in organic chemistry and is author/coauthor of various scientific papers and (co)-inventor of more than 60 patents. WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u BioMedPartners AG BioMedPartners General Partner, Speakers Roger Hill, Executive Director – Licensing and Business Development, Boehringer Ingelheim Roger Hill, responsibilities include identifying and Hill’s Dr. Global Licensing – As Commercial Executive Opportunities, Director & Head, executing Business Development & Licensing opportunities that add value to Boehringer Prescription Ingelheim’s Medicine Sterling at experiences R&D Area Therapeutic extensive Following markets. emerging and mature both in franchises CHC and Pfizer, at Development Business to transitioned Hill Dr. Development, & Research Global Pfizer and Pharmaceuticals Winthrop and in 2008 joined Boehringer AsIngelheim, USA. based ain BusinessRidgefield, CT, Development & Licensing executive Roger has expertise in product sourcing, due diligence, contract negotiations and legal transactions. Prior CardioMetabolic multiple to for responsibility 2007 Hill leadership Dr. with Pfizer at Director Area Therapeutic Development & Research a was disease areas, including Cardiovascular and Hill Frailty. Dr. was recently nominated to the Irish Government’s 2010 “Life Science Top 50” recognizing influential Irish Americans in life sciences. He Boston. holds Finance from Northeastern University, a and an MBA in Hi-Tech Ireland, Ph.D.University College Dublin, degree in Pharmacology from Boehringer Ingelheim Investment Manager, Wicke, Ilka Wicke Ilka joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery approaches. She later joined the Corporate Licensing Division of Boehringer Ingelheim where she over the 10 years last gained extensive experience in the evaluation, negotiation and the management of global licensing transactions. Subsequently Ilka joined the Corporate Licensing group as head of the business advisory teams for urology oncology, and opportunities licensing clinical and pre-clinical of evaluation and identification the for responsible was she where metabolism as well as agreements. structuring licensing global of and variety a of negotiating conclusion and negotiation the technology for responsible was and she where Licensing licensing Corporate agreements. She later joined the transaction group of Ilka has a PhD in organic chemistry from Goethe Wolfgang the University Johann Following in her Frankfurt. graduation she spent a year as a postdoctoral fellow at the Sloan Kettering investigating Cancer retroviral Center gene York in therapyNew approaches to stimulate antitumour responses. Markus Hosang, Markus Hosang Dr. is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad in and research pharmaceutical in as well as business, capital venture the of aspects operational and strategic in knowledge many product development and marketing with areas, special expertise in the areas of strategic biotechnologies, alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Hosang companies. Dr. portfolio was European several a of Venture boards the Partner on served at and MPM flow, Capital, deal European their for co-responsible was he where Pharma the in positions management senior several held he years, 20 nearly for where, Basel, in Roche at was he Previously, R&D organization, Vice including President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a VP and CSO member of the Roche Genetics Executive Committee. of Genetics and Integrated Medicine, and a He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University servedBoard Hosang the on Dr. Seattle. in Washington of University the atsubsequently and neurobiology in School Medical Treasurer its as (SSMBS) Biology and Medicine in Stipends for Foundation Swiss the of Trustees of Board the and Directors of from 1994-2002. He currently is a member of the boards of Avontec GmbH, Okairos AG and Suppremol GmbH. Earlier he articles 30 than more published has He Atugen. and IDEA ViaCell), with merger its (until Kourion Omrix, of boards the on was and is coinventor on several patents. in peer reviewed journals, Bellevue Asset Management LLC Asset Management Bellevue Portfolio Manager, Eric Bernhardt, Eric Bernhardt joined Bellevue company, Asset the Management joining Before in 2009 Healthcare. and and has Technology overall Medical management responsibility Biotechnology, for sub-segments the the comprises Healthcare which segment, managedhe investment where Management, Asset Leu Clariden with was 2007 to 1997 from and forBär worked Julius he funds specialized in healthcare, biotechnology and generics. Prior to that, he was a pharmaceutical analyst charter holder. Eric Bernhardt earned a degree in forest engineering from the ETH in Zurich and is a CFA and manager at UBS. portfolio WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Speakers Pnina Fishman, CEO, Can-Fite BioPharma Laboratory the headed and Sciences Life of professor a previously was and Can-Fite of founder scientific the is Fishman Prof. very a is Fishman Prof. Center. Medical Rabin Institute, Research Medical Felsenstein the at Immunology Tumor and Clinical of accomplished scientist and has authored or co-authored over 140 publications and presented the findings of her research at many major scientific Her meetings. scientific work was the foundation on which Can-Fite This was scientific built. work diseases. inflammatory and cancer for therapies generation new for approaches leading the of one as recognition gained has Her past managerial experience included seven years as CEO of Mor Research Application (MRA), a company that was in charge of commercialization of intellectual property from all hospitals and research centers of Clalit largest and healthcare was provider also in the Israel, first She clinicalwas CRO also in involved Israel. Health in the establishment Services, the and served on the Board of Directors of several life sciences technology start-ups. Drew has gained a broad base of executive leadership and business development experience working in entrepreneurial as well as major U.S. and International medical device and diagnostics companies. In addition to his 15 years in senior level Sales and Marketing positions, he has served as CEO/President, COO, and Board member of several medical device and one of which he co-founded with business partners in the UK. diagnostics companies, women’s of future the changing on focused company a International, CerMed of COO VP, Executive as serving currently is He health specifically in the area of cervical cancer screening the protecting he against served the HIV Previously, for virus. six co-founded, he which company, defibrillation cardiac access” “public a Technologies, HeartSine of, CEO & President as years led from start-up to commercialization, secured several rounds of venture funding and currently serves as Prior a Director. to that an he early servedCEO stage & Inc., Point-of-Care Chairman as Diagnosticsof President, SenDx Company, Medical, where he competently managed a turn around of the business resulting in consistent growth and the eventual sale of the ApS a leading provider of acute care testing solutions headquartered in Denmark. Company to Radiometer Medical In addition to level “C” his management experience Drew has an extensive global background leading sales and marketing driven organizations where he assumed and succeeded in positions of increased managerial responsibility by consistently driving significant growth in revenue and earnings. He served 5 years & as COO Executive VP, of E for M, Medical a NASDAQ listed Medical Device Company focused in the diagnostic cardiac areas imaging electrophysiology, of and interventionalpatient During monitoring. cardiology, this time he strategic various and growth organic both from stemming earnings and revenue in increase significant a for responsible was alliances and acquisitions, which resulted in a substantial increase in shareholder value and a profitable exit. Just prior to and thatmanufacturer of he diagnosticserved VP 5 Sales years & as Marketing developer, a for leading Burdick U.S. Corp., more than doubling both revenue and earnings where he managedsignificant up-turn in the business, a cardiology devices, during his tenure and leading to the sale of the business to Siemens medical one of the leading world’s manufacturers of medical equipment headquartered in Germany. He is an active participant in various business networking and mentoring International programs of area the in in studies graduate undertook California.. also he He where Baltimore of has University the from a Management Industrial BS degree in Marketing and Economics. Executive VP & COO, CerMed International VP & COO, Hofmann, Executive Drew Bristol-Myers Squibb Bristol-Myers Transactions, Strategic Lubor Gaal, Executive Director, Lubor is Head of Europe, Search and Evaluation and in addition, responsible for Neurosciences. He Global Transactions, is BMS’ point person forpharmaceutical or biotechnology Europe. companies in Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d, France and CBO of Vectron Therapeutics AG, Germany. In the Francisco, San in Company US, and Burrill for Lubor worked he Berlex, worked joining Before forAG. Schering of Berlex Licensing CNS and Cardiovascular Laboratories (NJ) where he was responsible for Global where he advised biotechnology and pharmaceutical companies on business development strategies and execution. Lubor has extensive experience in evaluating and negotiating transactions with New Jersey and in Europe since the 90’s. small California, and large companies, having worked in Lubor received his Ph.D. from the University of California at Berkeley and his B.Sc. in Neuroscience from the University of U.K. Sussex in Brighton, WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Speakers Delenex Therapeutics AG Therapeutics Delenex Chief Scientific Officer, Kretzschmar, Titus Titus Dr. Kretzschmar graduated from the University of Hannover/Germany in 1992 (PhD; working in biochemist). the biotech/pharma Since environment. Main affiliationsthen include thehe Ciba-Geigy AG (Basel), whereis he set up systems where the work with phageAG (Munich-Martinsried), as well as the MorphoSys for selection of antibodies by phage display, display resulted in the commercialization of the HuCAL GOLD® antibody In libraries. 2004 he was appointed to head R&D a profitableAG, of biotech firmthe thatamaxa provided leading devices and protocols After for the Nucleofection® of cells. the acquisition of amaxa by the Lonza AG in 2008 he became Lonza’s CSO & Head of LIFT (“Lonza In Innovationthe beginning of 2010 he decided to return to forthe biotech world Therapeuticsjoining Technologies”). as CSO the Delenex Future AG based in Zurich-Schlieren, a VC-financed company founded in September 2009 that develops the next generationA financing round by securing in In May antibody 2011 fragmentsDelenex concluded its forSeries therapeutic applications. of total CHF 30.2 millions (USD 34.8; EUR 23.5). CEO, & CSO, DCPrime BV & CSO, CEO, Ada Kruisbeek, Ada Kruisbeek founded DCPrime in 2005 and is responsible for the overall management and strategic decision making of DCPrime. She has more than 30 years of managerial experience in science and business, and is an expert in immunology Kruisbeek Ada industry. in later and settings, academic in first cancer, against immunity to dedicated been has career whose worked at the National Institutes of Health, Bethesda, MD, USA, from 1978 until 1992, revealed at how the the immune forefront system of develops. She research then became that Head of the Department of Immunology at the Nederlands Kanker Instituut-Antoni van Leeuwenhoekhuis (NKI-AVL) in Amsterdam from 1992 till 2001. She published close papers, to many 140 of which appeared in peer-reviewed top-journals, and served on multiple international advisory scientificboards agencies,of researchnational institutes andand companies.closed Crucell Inwhen 2004, 2001,In shepipeline. antibody cancer movedthe up building for toresponsible industryBV, Crucell andat Research Vice-President became Senior Transfer Technology the founded and Amsterdam, in (VU) Universiteit Vrije the to moved Kruisbeek Ada programs, oncology its In less than 5 Amsterdam in 2007. and the Life Sciences Center DCPrime in 2005, VUmc in 2004, VU & Office (TTO) for the years, she succeeded in making DCPrime a clinical DCPrime stage closed company. its first financing round in September April 2011. AML in 2010 and started a Phase I study in CEO, Curetis CEO, Oliver Schacht, Oliver Schacht, PhD, has spent more than 12 years in the molecular diagnostics industry. He had a at distinguished AG Epigenomics which he career co-founded in He 1998. served as CFO of AG Epigenomics Germany) (Berlin, from 1999 until 2011 and as CEO for Epigenomics, Inc. (Seattle, USA) from 2006 until 2011. He has an extensive track record in strategy development and implementation, fund-raising (including VC rounds, IPO, PIPE, Public Rights Offerings), corporate finance, M&A and alliance negotiation. During his tenture J&J and others. at Pfizer, Merck, Sysmex, Quest, Epigenomics QIAGEN, Abbott, alliances with the likes of Roche, Oliver was instrumental in negotiating and managing multi- prospective large, a including studies, clinical several in involved was CEO as managingwhile Oliver Inc. Epigenomics center trial in colorectal cancer screening in the USA and Germany. Oliver built screening IVD test kit. first blood based colorectal cancer launched the world’s a marketing and sales organization that London, and Reutlingen in Business of School European the from Administration Business European in diploma a holds Oliver as well as a Master’s and Ph.D. degree from the University of Cambridge (UK). During his tenure at Mercer Management Consulting (1995 until 1999), he worked internet, biotech, as such fields on in companies start-up several of co-founder a also is projects Oliver sectors. other and in biotechnology, M&A, growth strategies and reorganization in pharmaceutical, and education. Covagen AG Covagen CEO and Co-Founder, Julian Bertschinger-Ehrler, Dario Julian Bertschinger joined the group of Prof. biologyAfter his studies in molecular and biochemistry at Zurich, ETH DisplayThere he co-invented Covalent DNA student. Neri atPharmaceutical Sciences ETH Zurich as a Ph.D. the Institute of Covalent DNA Display he continued developing fellow as a postdoctoral in May 2005, his Ph.D. After obtaining technology. from more than 100 applicants Julian Bertschinger was selected the as one of In June 2006, group. Dario Neri’s in Prof. This enabled him to join a training program in the founded Leaders Prize by the Gebert Rüf Stiftung. Venture winners of the Bertschinger has been serving Julian Since 2007, course in entrepreneurship atBoston area (USA) with a Babson College. as CEO of Covagen. WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Deloitte LLP Speakers Kees Been has served as president and chief executive officer since 2005 and brings more than 15to years EnVivo. ofPrior experience to joining EnVivo, Kees was chief executive officer of Bionaut Pharmaceuticals, a biotechnology company using a proprietary cell-based discovery Prior to his work platform to advance drug candidates for cancer and inflammation. at Kees Bionaut, spent four years at Biogen where he directed the Oncology Business Unit as and, senior vice president of business led development, all deal-making of efforts Biogen’s and portfolio management Major activities. deals he oversaw include the collaborations with Elan on Antegren® with (now Tysabri®), ICOS on the oral LFA-1 antagonist, and with EOS Biotechnology Before on his breast work Kees cancer with held target Biogen, executive discovery. positions with Monsanto pharmaceuticals involving corporate modification projects and Prior large toLife growth that, the Sciences strategies America. Company, in Latin building for responsible was and president vice as served last he where Consulting Gemini at worked Kees an earned He Switzerland. Geneva, in Biogen at project Interferon-gamma the on scientist a as career his began He practice. degree M.B.A. from INSEAD in France and a degree B.S. in Molecular Biology and Process Engineering from the University Agriculture in Holland. of President & CEO, EnVivo Pharmaceuticals President & CEO, Kees Been, Head of Life Sciences Advisory Initiative, Switzerland, Advisory Initiative, Head of Life Sciences Jason Rushton, Advisory at initiative. Deloitte and leads the Swiss firms life science Corporate Finance Jason is a Director, management consulting and venture capital. R&D, in the pharmaceutical sector spanning Jason has 18 years of experience pharmaceutical advised he where Group Consulting PA to moved then and Lilly Eli with discovery drug in career his began He commercial For / the due biotech lastdiligence clients 10and in yearsfinancialtechnical, Jason transactions. has been an venture the with latterly transactions science life 30 over completing in involvement direct with investor capital venture active capital fund of Nestle. Jason spent several years as a board member of two biotech companies and has firsthand experience of pharma business development and licensing. Health & Biotech Equity Analyst, Equity Development Ltd Analyst, Health & Biotech Equity Castellón, Lorenza Lorenza Castellón is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed companies SMEs in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations. Equity Development brings together investors and companies by means of writing and distributing detailed research. provide We the markets with both facts and opinions along with fair valuations based upon diverse Over the and last decade our appropriatebrand has become synonymousmetrics. with quality objective research and we have built close links with institutions across the UK and Europe; like them we are Our fullyteam regulated. of analysts are FSA approved and boast a cumulative 400 years of Please experience. visit forwww.equitydevelopment.co.uk more details and examples of our work leading for worked having sector the in experience of years many have I and analyst biotech & health the am I me. contact or international investment organisations. WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Speakers Forbion Capital Partners Partner, Takke, Christina is Partner at Takke Forbion Christina Capital Partners and joined the AMRO team ABN Capital at Life Sciences as analyst in 2000. Before that Christina worked with Bio-Gen-Tec-NRW in Cologne, Germany, a Here she evaluated business proposals and assisted companies in the fundraising process. regional biotechnology industry. development organization for the At Forbion Christina is responsible for scouting and analysis of new investment opportunities as well as execution. the general deal Christina serves on the Supervisory Boards of arGEN-X and she Pieris. Previously, was on the board of Bioceros and was closely involved with GlycArt (sold to Roche in 2005) as Observer. Christina began her scientific career with a master’s degree in biologysubsequently from joined theTechnical University the of group Darmstadt. She of Prof Dr, Campos-Ortega where she studied at the Cologne, Delta-Notch signaling pathway and its role during zebra fish neurogenesis and early somite the Institute of Development Biology of the development. University of GILDE Healthcare Partners GILDE Healthcare Partner, Arthur Franken, C. by (acquired FlowCardia Pharmaceuticals, Conatus in investments the led Franken Mr. 2001. in Gilde joined Franken Arthur including divestments and investments numerous in involved been has He Laboratories. MTM and BCR)) (NYSE: Inc. Bard, R. Neuro3D (acquired by Evotec) and Pieris. IDEA, BG Medicine, AMT (IPO on Euronext), Agendia, Ablynx (IPO on Euronext), Mr Franken represents Gilde on the board of He MTM servedLaboratories. as a board member for FlowCardia (acquired by AMT (IPO on Euronext). Agendia and BCR)) and observed on the boards of (NYSE: Inc. Bard, R. C. Prior to joining Gilde Mr. Franken gained molecular in experience specialized Franken Mr degree, his During in Netherlands. the cardiovascular University, Leiden from Sciences Biopharmaceutical research at TNO. He holds a masters degree in toxicology at the departments and of Toxicology Biopharmacy in the Leiden/Amsterdam Center for Drug Research. He is a Dutch national. Excellentia Global Partners Managing Partner, Beth Jacobs, Beth is the founding Partner of Excellentia Global Partners, a global lifesciences-focused investment bank in In New York. her role overseeing origination and execution of private she placements, has an active dialogue with financial corporations, sponsors, venture capitalists, hedge funds and mutual funds. Beth is also involved arena. Partnering in the life sciences in cross border M&A, Licensing and Beth has served in senior executive roles in her twenty On the she advisory was most fiverecently side, Managing a Director life / science Partner boutique of BIO-IB, corporate sector. years ofexperience in both investment banking and in the investment bank in New Prior York. to 2003, Beth was Managing Director and Co-Head of Global Capital Markets at Barings, shortly ING after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity wide a for financings private and public many executed originatedand she Furman, and ING at While years. 7 over forgroup variety of issuers throughout Asia, including the largest 144A equity offering for a real estate company in (Empire the $210MM East initial Land’s public Philippines She offering). started her career at Prudential Securities where she founded the international institutional equity and business, later headed the same product execution group at both Morgan Stanley and Lehman Brothers. billion $3 a LAUR), (NASDAQ: Inc. Education Laureate for President Vice Senior recently most was Beth sector, corporate the In market cap company in the She educationworked across sector. all business units in a corporate development role with a Notablealternatives exploring included transactions for China. in opportunities on focusexecuting distinct and identifying on Street Wall Institute (a company owned by Laureate and later acquired by the Carlyle Group); initiating and executing a joint the largest hotel group development opportunities in China; and finding new acquisition and for venture with Jinjiang Group, Switzerland. hotel management training business based in Crans Montana, Laureate’s Les Roches, Beth DC received in an American conjunction MBA Washington, University with from in the School of Foreign a Service, BA, Switzerland. at and also studied the Centre d’Etudes Internationale in Geneva, from Boston College, cum laude, Beth serves as Vice Chairman of the Friends of the Budapest Festival Orchestra Board, Director of EF Research Foundation. von Liebig Medical William J. Foundation, Komen Foundation and Director of Global Ambassador for Susan G. WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Speakers Immune Targeting Systems Targeting Founder and Chief Executive, Immune Carlton Brown, qualified He sciences. life in background commercial a has and UK) (ITS; Systems Targeting Immune of CEO is Brown Carlton is Carlton 1997. in School Business London The from MBA his obtained and NZ) University, (Massey 1986 in veterinarian a as Since founding ITS Carlton has raised £14.5m vaccine platform. T-cell cofounder of ITS and co-inventor of the DepoVaccine worked he ITS to Prior company. based clinical a to concept in-silico an from development Company’s the led and funding of for SEDAC Therapeutics as commercial director and then COO, Dresdner Kleinwort Wasserstein has analystand an as strategicdevelopment in product Beecham Smithkline as director, corporatedevelopment as Plc Cortecs a marketing analyst, been involved in a number of other bioentrepreneurial activities. Stephanie Léouzon, Independent Consultant Stephanie Léouzon, She is currently a member Stephanie Léouzon is an independent consultant providing advice to life science companies. Partners, Torreya Advisor to and serves as a Senior of the Board of Directors of the French biotech company Endotis SA, Previously Banking in the US and Europe she worked in Health Care Investment a life sciences boutique advisory firm. She has advised life Advisor. most recently atSuisse as a Managing Credit Director and Senior from 1989-2010, been involved in over 45financing and valued at over $65billion, sciences clients on more than 20 strategic transactions, transactions to provide over $10 billion to health care clients. a and 1989 in Virginia of University the at Business of School Graduate Darden the from degree M.B.A. an earned Stephanie from Mount Holyoke College in 1985. cum laude, degree, B.A. immatics biotechnologies GmbH CEO, immatics biotechnologies Paul Higham, Development Commercial Director servedas he Previously, 2008. August in immatics of CEO as appointed was Higham Paul Therapeutics Group plc where he was Ark responsible for commercial strategyIn at and all business development activities. he was in addition, charge of establishing the operations Therapeutics and gene-based medicine Ark production facilities of in Finland. Therapeutics Prior Paul in Ark to Higham 2001, joining worked as Vice International President Commercial Metabolicfor GI, and Pain at GlaxoWellcome plc from 1996 to 2001, where he was responsible for all strategicsales Fromand marketing, he 1985finance. after held to completing various 1996, aspects his Applied studies Biology, in of business development, sales and marketing positions of increasing responsibility with AG Bayer and eventually became General Manager of Bayer Pharmaceuticals for Sweden and Denmark. Philippe Dro, CEO, GlycoVaxyn Philippe Dro, Philippe Dro joined GlycoVaxyn as Chief Executive Officer and member of the Supervisory Board in May 2008. He has 20 meditech companies. biotech and including pharma, in the life science industry, years entrepreneurial experience Most recently, he was Chairman and CEO of Endoart SA, a medtech company developing cardiac disease that and telemetric was obesity, sold driven to Allergan, Inc. From 1999 implants to 2003, Dr Dro for was Chief Operating Officer (COO) that grew the company to a clinical a GPCR focused drug discovery company, AG, AXOVAN and part of the founding team of Antares of Board the of director and COO of position the held he this, to Prior Ltd. Actelion by acquired was which entity stage Pharma, Inc (AMEX: AIS), a drug delivery company formed by the merger of Permatec held Group executive director positions at and Skyepharma Ltd during its Mediject, listing on the Inc. LSE and in He finance at Sandoz AG Pharma (now also Novartis). Lyon de Comerce de Supérieure Ecole from jointly MBA an and (France) Grenoble of University from D Pharm a earned Dro Dr (France) and Cranfield School of Management (UK). WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Speakers Katan Associates Katan Chaiman & Co-Founder, Yakatan, Stan After 30 years as a and has Stan Yakatan successful operational dedicated CEO, entrepreneur, manager, the last 12 years of his career to sharing his experiences with management teams interested in building technology based companies. His level executive is far reaching he has served in such a capacity with: “C” experience as a • Biosearch Dupont • ICN Pharma • New Brunswick Scientific New England Nuclear • EI These experiences have provided him with management skills and a corporate finance acumen that he enjoys sharing with others. Stan has founded or co-founded in excess of 15 companies in the United of several advised has States, he Canada, Israel, France and career, In his In Germany. companies. these of Chairman and CEO, initial the servedas also has he cases many During (Canada). Biocapital and (USA), MSP (USA), Ventana (Germany), TVM including firms capital venture leading world’s the Biocapital venture capital was the most successful fund in Canada. the decade of the 1990’s systematically Group Tech XL The XLT). (AIM: TechGroup XL the for capacity development business a servesin currently Stan liquidity. to them scales and businesses, technology new develops and selects, creates, then needs, business unmet discovers XL for strategy capitalization overall the on advised and model, business its of development the in TechGroup XL assisted Stan Alternative the on listing its with connection in Offering Public Initial an undertook TechGroup XL 2004, October In Group. Tech raising in excess of $40.0 million. Investment Market (“AIM”), Stan has completed and advised on numerous acquisitions and corporate finance transactions raising inbillion excessdollars ofin $1.0 the public “The and and private Start-Up” capital Technology-Based financing markets.the Hefor Raising is“Capital a including, frequenttopics on speakerspeaking world atthe financialthroughout conferences and biotechnology Need to be Global Yakatan in the Quest for Capital Editor Rick and of Biondi, Partners”. Lab Mr. Business Magazine stated,” is a venture capital his genetic make up.” raising Guru and it is part of Stan is currently the Chairman of Grant (OTCBB:GLIF) Life Inc., a Sciences, company developing a revolutionary test for the Stan screening is of also cervicala member cancer. of the Board of Stan Directors (OTC.BB). servesof Inc. Biophan, as the Biocomm, of Chairman and Director Executive the also is Stan Australia. Victoria, of Government State the to advisor strategic currently Stan pool. capital early-stage and agency development business regional kind its of first the Australia, Melbourne, in and Phenomenome which is developing new drugs sits Inc. foron the diabetes Board Therapeutics, of and Mercuryobesity, a novel biomarker company. Inc., Discoveries, Merck Serono Ventures Serono Head, Merck Roel Bulthuis, Roel Bulthuis the is strategic Head of venture Ventures, Merck capital Through Serono groupthe ventures of Merck Serono. group, Merck Serono is committed to actively invest in emerging biotech companies which have innovative the core products or therapeutic in access Merck areas, Ventures to Merck Serono’s innovative Serono technologies. potential to provide Banking Investment Biotech the in Director a was Roel Previously, BioIncubatorFund. Israel Serono Merck managesthe also at Fortis where Bank, Team he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New Roel Belgium. holds in a York. and the Biopharmaceutical Msc. an Netherlands, Sciences Before MBA from in Leiden Finance University, that, he worked at Devgen in Ghent, Finland. from the Helsinki School of Economics, Molecular Partners AG Molecular Partners CEO, Christian Zahnd, Christian Zahnd (Switzerland) is Chief Executive Officer and member of the board of directorsfrom ofPhD his earned MolecularZahnd Christian After Partners. Lynch, Merrill for working and Zurich ETH the from science of master a with graduating His main interest which was the he on University studied antibodies in of and Zürich. own antibody research fragments, and in academic and industryPioneering therapeutic collaborations. applicationshe co-founded of Molecular DARPins, Partners and was a member of the management from the early days. WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u 10’000, €10’000, negotiating and finalising all contracts (research, license, collaboration, clinical trials, services) above services) trials, clinical collaboration, license, (research, contracts all finalising and negotiating Speakers  structuring, including important license agreements with research institutions and pharma/biotech companies in Europe, Japan and the U.S. Director Business Development and Investor Relations, Director Business Development MolMed S.p.A. Holger Neecke, company biotech clinical-stage a S.p.A., MolMed at Relations Investor & Development Business of Director is Neecke Holger developing novel therapies against Exchange. cancer and listed on the Milan Stock particularly by: in biotech business development, He has acquired a broad expertise 2001. He joined MolMed in October • • assessing market potential of products and performing• assessing market potential DCF-based portfolio analysis • leading the project management of clinical-stage products and roadshows in company the representing Relations, Investor MolMed’s for responsible also is Neecke Holger 2007, Since and defining the annual IR communication plan. at investor meetings, Since he 2004, is lecturer of a 16-hours course in Business Strategy at the “Vita-Salute Univerisity San School Raffaele” of Biotechnology).Medicine (course in Medical and Pharmaceutical and developed he where Milan, in agencies transfer biotech a Scrl, Biopolo at worked Neecke Holger MolMed, joining Before evaluated business plans for start-up companies. Holger Neecke holds a degree in Molecular Biology from the University of Basel, Switzerland, a PhD in Genetics Milan. from and a MBA from SDA Bocconi Business School, University of Milan, the Senior Director, Scientific Liaison, Licensing and External Research, Europe, MSD Europe, Licensing and External Research, Scientific Liaison, Senior Director, Beer, Margaret Margaret Beer studied at the Universities of Stanfordfrom UK followingthe University. 1984 to in return her neuroscientist, bench a as Reading Merck, joined She pharmacology. and London before carrying out her and research MAXALT drug anti-migraine Merck’s work of development the for responsible team on the of members founding the serotonin of one is She research of areas main other Her 1997. in launch the to stagethrough research basic the during project the in involved was anxiety and multiple sclerosis. interest include depression, Margaret joined Worldwide Merck’s Licensing and External Research, Europe, group in This 2003. group was established in 2002 specifically in recognition of the scientific excellence in Europe and the wealth of potential licensing opportunities. Margaret assumed leadership of the group in 2008. international at widely presented has and abstracts, and articles, review articles, research original 100 of co-author the is She professional meetings. Global BD&L, Head Search & Evaluation Neuroscience and Opthalmic, Global BD&L, Alethia De Leon, Pharmaceuticals Novartis Alethia de Leon currently leads globally the BD&L search and Business evaluation at efforts Novartis for Pharmaceuticals. the Before Neuroscience this role, and she Ophthalmics was part of Previously the she worked led Partner Venture as forBiotech VC, a investments a for Biotech a private equity Strategy fund of funds and team at Novartis Pharmaceuticals. She Corporation. Bayer and Idec Biogen Biologics, Therion in BD&L and development process R&D in roles various in worked holds a and B.S. in M.S. Chemical Engineering/Biology from the and Massachusetts an Institute from Technology M.B.A. of as well She has also performed research at the BiotechnologyHarvard Process Engineering Center at MIT, Business School. as at the Department of Materials at ETH. CEO, Neuronix Medical. CEO, Eyal Baror, executive- in and R&D in experience of decade a over brings Eyal servesBaror 2009. of Summer of as CEO Neuronix as Mr. Talpiot Force’s Defense Israel prestigious the graduateof a is Baror Mr companies. devices medical several in positions level cum (summa Physics in MS a and Jerusalem, of University Hebrew the from (cum-laude) Physics in BS a holds and program, University. Tel-Aviv laude) from the WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Speakers Oxford BioMedica plc Oxford Activities & Strategy, Director of Corporate Lewis, Alex Alex Dr Lewis is an experienced consultant to the pharmaceutical and biotech industry with a background of over 24 years in medical research and drug development. Alex was appointed to Oxford BioMedica’s Board in April 2008 and was also Director and of Transactions Due Diligence at The Datamonitor Group until June 2009 when he became Director of research Mackenzie Lewis Wood of practice Diligence Due and Partnering the of Head was he this, to Prior Consultants. Healthcare Alex has also been involved in the provision of expert reports and technical advice consultants. for the initial public offerings and fundraising activities for biotech companies based in the US and Europe. Novartis Pharmaceuticals Alliance Management EU, Novartis Head of Strategic Esteban Pombo-Villar, Esteban Pombo-Villar PhD CChem FRSC His group is responsible Reasearch for is (NIBR). managing research and early development collaborations with academic and Head of Warwick Alliance of University the from Chemistry Organic in Management PhD his obtained Pombo-Villar Dr world-wide. groups at biopharmaceutical the Novartis Institutes for BioMedical in the After UK. postdoctoral studies at the ETH in Zurich, he joined Sandoz Neuroscience Research in Basel in 1988, and worked on drug discovery projects as well as leading collaborative projects for investigation of emerging technologies. He was External Collaborations Manager for and Neuroscience, from was 2003, Head of StategicAlliance Management based Switzerland. in Basel, Novartis Venture Funds Venture Novartis Managing Director, Anja König, Anja König Dr. is active in Switzerland and Europe and also responsible for expanding the fund’s presence to Asia Pacific. Novartis. of CEO and Chairman the to assistant of position the held she Fund Venture Novartis the to appointment her Before Prior to joining Novartis she was by scientist an a is AssociateKönig Anja Partner Markets. Emerging and at Europe US, the McKinsey in biotech and & pharmaceuticals, Co., care, health in a companies global consultancy, where she worked with University. training and holds a PhD in physics from Cornell Oxford Finance Oxford Managing Director, Chris Herr, development business for responsible is He 2002. since team development business Oxford’s of member a been has Herr Mr. for life sciences and healthcare services companies worldwide. Before joining Herr Oxford, Mr. established the Southwest he had Previously, which operations provided life fordebt sciences capitalcompanies. Charter Financial, to venture-backed, been co-founder and executive vice president of Coghill Capital He Management. has taught numerous public seminars as well as lectured at Penn State University on the topics of equity portfolio investing, management and estate He planning. is Arts from Pennsylvania State in Liberal Herr holds a B.A. Mr. currently a board member on several privately held companies. School. from the London Business University and an M.B.A. NYSE Euronext NYSE International Listings, Business Development, Director, Isabelle Dubé-Côté, Ms. Dubé-Côté is a Director at NYSE Euronext, the leading global technologies operator with exchanges in of the US and financialEurope. Since joining NYSE marketsEuronext, Ms. Dubé-Côté has been andresponsible for provider of trading International Business Development, Client Coverage and Marketing for the group; both out of the New York and in Paris offices. and Financial Bank National the at Banking Investment & Corporate in worked Dubé-Côté Ms. Euronext, NYSE joining to Prior Markets in Canada. World at CIBC Ms. Dubé-Côté graduated from Concordia University with a B.Com degree in finance and completed an MBA atYork New University. WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Speakers Tim Sharpington, CEO, Phytopharm Sharpington, Tim Tim joined Phytopharm as CEO in July 2010 with more than 20 years experience in the pharmaceutical and biotech arena. Past companies include SequusPfizer, Inc, Arakis and Serentis. A clinical development professional by background,Tim has held leadership positions in private and public companies in both the US and a number fund-raising of rounds, M&A Europe. and product licensing deals and He has led a number of products through development has led public and private to registration. In addition to his position at Phytopharm Tim is a Non-Executive Director with Clinical Force, a clinical trials emerging companies. and advises a number of small, software company, Pevion Biotech AG Pevion Biotech CEO, Evert Kueppers, Before joining Pevion in Fall 2010, Evert Kueppers was CEO of Pieris AG, an alternative protein scaffold biotech company based in Munich that he successfully restructured and refinanced byinternational/US raising investors. Prior in total to Pieris, over he USD played, as 45 million Head from leading of development of liposome drug deliveryAG bybiotech Business IDEA signing the largest German licensing deal in 2003 with Johnson Development, a pivotal role MPM in investor, key its of the exit successful the and round financing D Series its for corporate basis the laid deal corporate This Johnson. & Kueppers worked Beforefour Capital. joining years Mr. the for biotech BASF industry, Pharma Abbott (now Laboratories.) in with consultant management a was subsidiary) and Argentine and headquarters German its at (both Operations International Biomedical in degree M.S. an holds Kueppers Mr. UK. London, in Kearney AT of team care health / pharmaceutical global the currently He Netherlands. The University, RSM/Erasmus from MBA an and Netherlands, The University, Leiden from Sciences Germany. Dresden, serves on the Board of Cenix Bioscience, CEO, Philimmune LLC CEO, Florian Schodel, Florian Schödel is the founder of Philimmune LLC, a consulting firm vaccines and pharmaceuticals. biologics, which provides strategic advice in the development of Florian has > 20 years of pharmaceutical and biotech industry and in academia. successful experience in leading teams in the development of His vaccines passion is and preventative medicine biologics and the in use of the modern science and technology for especially in the development of preventativeand therapeutic vaccines and biologics. the improvement of public health – Florian has a track record in running scientific and operational organizations, in business and strategic development. pre-clinical and clinical of steps identificationtarget all in in and planning,internationalstrategic alliances, and partnerships for forming He has directed the design and execution of clinical studies for licensure and routinely interacts with international and national regulatory agencies. Florian has led the clinical teams microbiologist by responsible training, Florian was for a VP in Vaccines several Clinical Research of successful Merck Research vaccine Laboratories before filings.he founded Philimmune. A physician and Florian graduated in medicine at the at appointments the faculty adjunct Munich, Technical University, holds and He (LMU). earned Munich of University doctorates the from habil.) in Transplantation Immunologymed. and Dr. med. (Dr. Microbiology Medical LMU WRAIR research and atat the atthe Florian’s Max-Planck Biodesign Scripps, Center Institute ASU. forof the Biochemistry, malaria and typhoid. and INSERM focused on hepatitis recombinant vaccines against B and on novel diseases such as hepB, Florian joined Merck Research Laboratories in 1996 (SP-MSD) as Vaccine Research Director leading Clinical venture EU vaccine clinical joint trials and EU an to liaison clinical the As vaccines. rubella and mumps measles, rotavirus, of development clinical the he participated in the development of pediatric combination vaccines. CEO, ProFibrix Inc CEO, Jan Öhrström, Jan Öhrström, MD is CEO and President of ProFibrix Dr BV. Öhrström companies has in EU 20+ and the years US. He biotech started his industry career at experience Novo Nordisk from A/S in 1990 and held various positions of seniority within increasing Development and Business/Marketing in Denmark and the Dr US. Öhrström joined the Senior Management Team at ZymoGenetics Inc in Seattle in 2000, and was actively involved in taking the company 2002 public and was (Nasdaq:ZGEN) responsible in for establishing the company’s development and business infrastructure. During his tenure at ZymoGenetics Inc, the company submitted its first BLA (RecoThrom©) that wasProFibrix in 2008 approvedand incorporated the company in in In the 2011 US he same 2008.was year. promoted to DrCEO and is overseeing Ohrstrom joined He is an MD from University of Copenhagen the and US completed 6 and Dutch years operationsof clinical of the company. practice prior to joining the industry. WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u

Speakers Guy Claude, Vice President Out-licensing and Special Projects Sanofi Guy Claude, Joined Pharmuka in 1980. Moved to Rhône-Poulenc Santé’s Licensing Business Development and Department Licensing based of in in Rhône-Poulenc Paris, Became 1994. Rorer, Deputy to Head in of BD and 1984. Appointed Vice-President based in Europe. Teams heading the Corporate Licensing in 2000, Aventis Licensing of of forms creative and appropriate other or deals Out-Licensing of up setting the for responsible is Guy position, current his In with the objective of generating long term value for Sanofi and its Partners. Collaboration, well as deal Licensing many managing, and/or negotiations, driwing been has he Development, Business in career his During as other forms of partnership. he is married and is the father of one son. Born 1955, Guy graduated from Business School in France and the UK. Ricerca Biosciences Ricerca Chief Financial Officer, Vice President and Executive Gary Jacobson, financial, the for responsible is Jacobson “Gary” Gerald Ricerca, for officer financial chief and president vice executive the As facilities and IT aspects of Ricerca. human resources, legal, He previously served as executive vice president and chief financial officer new of of president Harlan vice Sprague Inc., chief senior Dawley, operating and Bank National LaSalle of manager division and president vice senior Europe, Harlan of officer American National Bank. business development at and holds Jacobson a is certificatea graduate Adam inIllinois, politicalof economyKnox from College the in Galesburg, Mr. Virginia. West Huntington, in University Marshall from MBA his received He Scotland. Glasgow, in Economics of School Smith Sascha Bucher is based in Basel, Switzerland, and Deputy Head of Group M&A. In his role he is responsible for strategic across the Roche Group. mergers and acquisitions as well as divestments Having spent over 10 years at Roche Corporate Business Development Sascha has been leading a number of international M&A transactions many of which included early stage biotech and diagnostics companies and technologies including the recent acquisitions of BioImagene Medingo (USD (USD 100 200 mio), Marcadia mio Biotech incl (incl milestones), USD 500 milestones) as well as PVT Probenverteilungs GmbH (EUR 85 mio incl milestones). mio incl. Corporate Roche joining Before alumni. Harvard and Analyst Financial European Certified a is Sascha economist, an as Trained finance positions and in banking. Business Development he has worked in several Corporate Business Development, Roche Corporate Development, Business Bucher, Sascha Roche Venture Fund Venture Roche Fund, Venture Head of Roche Carole Nuechterlein, Carole Nuechterlein has headed the Roche Venture Fund since pharmaceutical/biotech 2001. as an attorney Prior for ten She years. joined Roche from to SangStat in Fremont California where she her was current position, she worked in the General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research to her collaborations background in and M&A, Carole licensing led the deals. negotiation Due team for the Roche acquisitions of and GlycArt Technology Idaho and Therapeutic Envoy, Human Conatus, Ambrx, Ambit, She currently Alios, Polyclonals. serves as a board observerAileron, at Venture Roche the on information More Michigan. of University from JD a and University Valparaiso from BA a has She Nereus. Fund can be found at www.venturefund.roche.com. WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS

t back :: next u Speakers Sofinnova Partners Sofinnova Principal, Woodman, Rob Rob Woodman joined Sofinnova in January 2007. Priorcompany development and transfer technology focused oncology an Ltd, to Sofinnova,Technology Research Cancer at team Management from 2005 – 2006, Rob source information pharmaceutical of worked in the Business Group Consultancy Management the in Analyst Business a was 2004 in and UK, the in IMS also Health, in the Rob UK. holds a PhD in Molecular and Cellular Biology / Oncology from the University of Cambridge and an MSc in Biochemistry from the University Inventions of made Oxford. PhD during were the patented;course of Rob’s reviewed journals. His research was published in peer this IP is now part of the foundations company. of a biotech Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals, President & CEO, Joanna Horobin, development the on focused company held privately a Pharmaceuticals, Syndax of CEO and President is MD Horobin Joanna Operating Chief and Sanofi) (now Rorer Rhone-Poulenc at Oncology of President Vice Formerly therapies. cancer innovative of multiple in experience development drug pharmaceutical of years 25 than more has Horobin Dr. Inc., CombinatoRx, of Officer with a focus on oncologyof combination and a particular interest in the development strategies. therapeutic areas, At Rhone-Poulenc Rorer she led the (docetaxel) and also led a successful joint venture with the Japanese Taxotere® company global of subsequent market expansion, oncology business, including directing the successful Chugai, Chugai global Rhone-Poulenc, which launch, developed and and launched the granulocyte growth factor Granocyte® (lenograstim) for the European market. As Chief Operating Officer at CombinatoRx, a company focusedraised onover $70 million combinationin private transitionedfinancing, products, the company she from a discovery-focused start-up to a clinical-stage Vice President Horobin was also Executive and positioned the company forDr. enterprise, a successful initial public offering. venture the with Residence in Entrepreneur as year a spent She inhibitors. angiogenesis developing company a EntreMed, at capital firm MPM Capital. Her pharmaceutical experience spans and clinical marketing, general development, management in both public and private companies. of Membership gained additionally and England, Manchester, of University Victoria the from medicine in qualified Horobin Dr. the Royal College of General Practitioners in the United Kingdom. She holds the Diploma of Pharmaceutical Medicine from the Royal College of Physicians in the United Kingdom. Santhera Pharmaceuticals Santhera CEO, Klaus Schollmeier, Klaus Schollmeier is Member of the Board of Directors Graffinity and Pharmaceuticals Chief AG Executive as Officer CEO of inSanthera. 2003 and Mr Schollmeier became joined CEO ofwere thecombined Companyto whenform Graffinity Santhera andin MyoContract2004. AG Prior to joining the director of biotechnology the healthcare/biotechnology industrygroup at ING-BHF in Bank for 2003, ING he Group Europe. Prior served to that, he as spent 16 managing years in His Knoll Abbott. scientificand responsibilitiesthe includedpharmaceutical headindustry of oncology/immunologyat BASF, Bioresearch BASF at biotechnology of director senior and Germany, Ludwigshafen, in laboratories central BASF’s at research Corporation in Cambridge, Massachusetts, US (1989 to 1993). His business functions included general manager of BASF 1994 From thereafter. Europe Western for manager general and president vice and 1998 to 1996 from Netherlands Pharma the from biology in PhD a holds Schollmeier Mr Pharmaceuticals. Boots of integration and acquisition BASF’s led he 1995, to University Boston the at professor associate research adjunct an became he 1991, in and Germany, Düsseldorf, of University Massachusetts. Medical School, ECM SPONSORS WELCOME

Speakers

Melanie Lee, Chief Executive Officer,Syntaxin

Melanie Lee’s academic grounding in molecular genetics in three complex systems of DNA repair and recombination, RNA VC PARTNER splicing and cell cycle was a broad and an important foundation for her future career. Melanie was cited by Sir Paul Nurse in his inaugural ceremony in Stockholm on receipt of his Nobel Prize for Medicine in 2001 for her contribution to his cell cycle work. Melanie’s industrial career has been through Glaxo, GlaxoWellcome, Celltech and UCB. During her career leading the discovery organization as well as Research & Development, for 6 years as a Board Director with Celltech plc and 5 years on the Executive Committee of UCB, Melanie has led R&D through 6 integrations. In 2008 she put in place the foundations of an innovative organization named UCB NewMedicines which is accountable from Discovery through to Proof of Concept for t back :: next u

small and large molecule drugs. Melanie is the Chair of Cancer Research Technology and Deputy-Chair of Cancer Research SPEAKERS UK. Melanie was honoured in 2008 with a CBE for services to Medical Science. Melanie believes that the pharmaceutical industry is undergoing a complete change of mindset and skills base as well as way of working which enhances the importance of biotech companies for the future of the new drug Research & Development. She believes that the importance of academia and industry (large & small) working together is crucial to innovation and advancing science and human health. Melanie is currently CEO of Syntaxin Ltd which she joined in February 2010. PRESENTING COMPANIES Graeme Martin, President & CEO, Takeda Research Investment Dr. Martin is President and CEO of Takeda Ventures, Inc. (TVI) with day-to-day responsibility for operations. With more than 30 years of pharmaceutical R&D experience in the Pharmaceutical and Biopharmaceutical industry (Wellcome; GlaxoWellcome: Hoffman La Roche; Telik), he joined Takeda in 2003 and has been instrumental in building the Company’s strategic venture operations based in Palo Alto, California. Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK.

Eduardo Bravo, CEO, TiGenix Eduardo earned his degree in business administration at the CUNEF(Madrid, Spain) and also holds an MBA from INSEAD

(Fontainbleu, France). PARTNERING ORGANISATIONS He brings more than 20 years of experience in the pharmaceutical industry, during which time he held several senior management positions. He was previously Vice President for Latin America at Sanofi-Aventis, where he was responsible for over than 2,000 employees and more than €1 billion in sales. At Sanofi-Aventis he also held the positions of Marketing and Sales Manager for Europe and General Manager in Belgium. Eduardo also worked for 7 years at SmithKline Beecham in both national and international commercial roles. In July 2005 he joined the Genetrix Group as Managing Director, and subsequently in 2006, was appointed CEO of Cellerix where he was also a member of the Board of Directors. Cellerix was a biopharmaceutical company founded in 2004 as a spin-off from the Genetrix Group and focused on the development of innovative cell therapies. He was appointed CEO of TiGenix NV in May 2011 following a business combination of Cellerix and TiGenix to create a new European leader in the field of cell therapy, and is a member of the TiGenix Board of Directors.

Lukas Guenther, Principal, Life Science Team, Wellington Partners EINLPRNR ORGANISERS REGIONAL PARTNERS With an international background in clinical medicine and economics, Lukas has an excellent foundation for identifying the most promising investment opportunities. He joined Wellington in 2007 as a Principal in the Life Science team and focuses primarily on deal flow management and due diligence processes. Prior to joining Wellington, Lukas had worked for six years as a surgeon and clinical researcher specialising in organ transplantation at the department of surgery at the Universities of Heidelberg and Freiburg. From 2000 to 2002, Lukas was a post-doctoral scientist at Harvard University in Boston, where he conducted research in the fields of immunology and protective genes. In 2003/2004, Lukas also completed a fellowship in clinical islet transplantation at the University of Minnesota in Minneapolis participating in NIH multi-centre trials. Lukas studied Medical Sciences in Berlin and Cape Town. He holds a doctorate in Medicine from the Humboldt University Berlin and a Global OneMBA degree from RSM Erasmus University, Rotterdam.

WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

or the treatment of Hodgkin’s lymphoma has entered clinical studies in 2010. So far there were lymphoma clinical studies in 2010. has entered or the treatment of Hodgkin’s AFM 13 f appearedThe product to be safe and well tolerated. more than 15 patients treated. • AFM 11 for Non-Hodgkin’s lymphoma is currently in late stage preclinical development. AFM 11 for Non-Hodgkin’s • • Development strategy: We are planning to finalize the ongoing study in 2012 and to further develop AFM 13 in a develop are planning to finalize the ongoing study in 2012 and to further We Development strategy: We are furthermore seeking co-development pivotal Phase IIb study for 3rd line treatment (finalized in H1 2014). partners to conduct studies for treatment 1st and 2nd line of HD. PoC (finalized in H1 2014). AFM 11 the product will be developed until clinical MANAGEMENT CEO Adolf Höß, Dr COO Dr Rolf Günther, CSO Prof Dr Melvyn Little, CFO Dr Florian Fischer, Affimed Therapeutics AG Therapeutics Affimed www.affimed.com FINANCIAL SUMMARY A/S. BioMed Invest and Novo Nordisk LSP, Aeris, are backed by a peer group of investors including Orbimed, We are currently raising 25M€€ in a Series D financing for the outlined clinical development. We PROFILE COMPANY TandAbs as novel and improved treatments Affimed is a clinical stage therapeutic antibody company developing and product efficacy excellent targeting molecules are bi-specific human antibodies with TandAb in oncology. Robust GMP increased therapeutic possess to monoclonal antibodies. potential compared TandAbs stability. show an TandAbs studies, Tox In pre-clinical production and downstream processes have established. been entered clinical trials in 2010. excellent safety profile and its first product has Affimed´s lead product candidates comprise: YEAR FOUNDED Affimed was founded in 2000 in Heidelberg as a spin-off from the German Cancer Research Centre and employs Heidelberg, (DKFZ), 28 people. Assistant: Assistant: [email protected] [email protected] EMAIL [email protected] FAX +49 6221/65307 77 TELEPHONE +49 6221/65307 0 ADDRESS AG Therapeutics Affimed Im Neuenheimer Feld 582 69120 Heidelberg CONTACTS Florian Fischer Dr. Chief Finance Officer Claudia Heisch / Treiber Daniela Assistants WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Affitech A/S Affitech www.affitech.com FINANCIAL SUMMARY Cash and cash thousand. total assets amounted to DKK 92,390 Affitech Group’s the 2011 On 31st March, Affitech completed a April 2010 2011 In DKK 50,453 thousand on 31st March, equivalents amounted to directed share offering which provided DKK 156.1 million in net new equity. PROFILE COMPANY inflammation and other drugs based on fullyAffitech discovers and develops human antibodies for cancer, discovery efforts The Company’s therapeuticsserious diseases where antibody can be beneficial patients. for phage libraries and proprietary screening platformsutilize its fully integrated repertoires, antibody expression both internallyand biotechnology and in partnership with pharma companies. A/S has built a substantial pipeline of early stage fully human antibody therapeutic drug candidates Affitech is an anti-VEGF antibody AT001/r84 Lead compound using the MBASTM and CBASTM screening platforms. AT001/r84 VEGFR1 remains unharmed. VEGF with interaction of VEGFR2 while VEGF binding to that inhibits AT008/anti-CCR4 are currently in being developed first GPCR targeted antibody program and the Company’s collaboration Generium. with Russian Biotech partner IBC MANAGEMENT Managing Director Welschof, Martin Chief Science Officer Alexander Duncan, Chief Financial Officer Stig Jarle Pettersen, YEARS FOUNDED Affitech Re- 2009 (Combination of AS Norway and Pharmexa search A/S Denmark) EMAIL [email protected] [email protected] [email protected] FAX + 47 22 95 83 58 TELEPHONE +45 3917 8259 Welschof Martin +47 95128237 Randi Krogsgaard +45 23201001 ADDRESS 3 Vej Ole Maaløes DK- 2200 CPH N Denmark CONTACTS Welschof Martin Managing Director Randi Krogsgaard WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

y is debt free with current assets in cash and cash equivalents at year-end of $423k (2009: $2.6 of $423k (2009: assets in cash and cash equivalents aty is debt free with current year-end Compan  million) – Cash position subsequently increased by in February the £2.16 million placing 2011 PROFILE COMPANY Stock Exchange in AIM of the London ABI was founded in 1989 in the United States and gained admission to 6 proprietary formats platform technologies merge scientific innovation with user-friendly The Company’s 2002. 2010 was a very to deliver cost-effective solutions where and when they’re and time-efficient testing needed. ABI is well-positioned to complete the clinical into 2011, Moving new product pipeline. ABI’s productive year for development of a number of novel rapid diagnostic testing solutions and introduce these products into high value towards the end of the year and beyond. markets, MANAGEMENT Senior Management President and Chief Executive Officer Nicolette, A. Thomas Vice Chairman Executive PhD, Jr., Akers, Raymond Corporate Controller Gary Rauch, Operations Vice President, Lee Meyers, Marketing Vice President, Patrice Laterra McMorrow, Akers Biosciences, Inc Biosciences, Akers www.akerbiosciences.com – 2010 FINANCIAL SUMMARY $1.8 million) to $3.1 million (2009: – Revenue increased 72% 40.3%) – Gross Profit Margin increased by 18 basis points to 57.8% (2009: $4.6 million) substantially reduced by to $1.2m (2009 loss: 74% Tax Adjusted Loss Before – $4.1 million) $649k (2009 loss: increased by loss: 84% to – EBIDTA – YEAR FOUNDED 1989 EMAIL [email protected] FAX +1.856.848.0269 USA TELEPHONE +1.856.848.8698 USA +44.20.7917.9476 UK ADDRESS Inc. Akers Biosciences, USA 201 Grove Road New Jersey 08086 Thorofare, UK 212 Piccadilly W1J9HG London UNITED KINGDOM CONTACT Nicolette A. Thomas Mr President and Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

AM-Pharma B.V. AM-Pharma www.am-pharma.com FINANCIAL SUMMARY C-round 2007: €7M ~ €29M D-round 2011: PROFILE COMPANY Acute Kidney Injury (iv) and Alkaline Phosphatase for treatment of recombinant human AM-Pharma is developing severe Ulcerative (oral) Colitis Alkaline Phosphatase is being developed as an intravenous (AP) solution for the treatment of acute kidney injury (AKI). There is no AKI is a condition that affects 2 million patients annually and kills nearly 700,000 annually. AKI. therapeutic approved for the treatment of AP reduces the need for Clinical data demonstrates from two independent phase-II studies that treatment with AKI. AP would be the first drug on the market to treat dialysis compared to the placebo group a factor two. with Also a significant improvement in patient was observed condition in the treatment group. Alkaline Phosphatase demonstrated similar efficacy orally administered In an open-label Ulcerative Colitis study, and 26% remission rate AP showed 79% response at score Truelove-Witts Measured with the as infliximab. week 9. Thereafter further clinical studies will AP source. AP to a recombinant The company is now switching from bovine AP. be conducted to establish the recombinant human proof-of-concept with ‘composition of matter’ ‘method-of-use’ and AM-Pharma has a solid patent portfolio of multiple consisting patents. MANAGEMENT Senior Management CEO Erik van den Berg, VP Clinical Development Arend, Jacques VP PreClinical & Manufacturing Steve Connor, YEAR FOUNDED 2002 EMAIL [email protected] assistant: [email protected] FAX +31-30-2289220 TELEPHONE +31-30-2289222 +31.6.11646554 cell: ADDRESS AM-Pharma B.V. Rumpsterweg 6 AK Bunnik 3981 The Netherlands CONTACTS Erik van den Berg Chief Executive Officer Raffaella Balena Assistant WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Amakem NV Amakem www.amaken.com FINANCIAL SUMMARY Action platform focused on in 2010 to establishSeed financing of 1.5M€ of concept of the Localized Drug proof inhibitors forthe development of ROCK the treatment of COPD and inflammatory eye diseases. proof of concept. to clinical AMA0076 for glaucoma. develop A investment to 18M€ series Life Science Vinnof/PMV, LRM, BioCapital, Vesalius Agricole Private Equity, Crédit Forbion, A investors: Series Research Partners. PROFILE COMPANY Amakem’s Amakem is an ophthalmology company new treatments developing for serious eye conditions. Action platform generate which is designed to safe Drug product pipeline is based on its unique Localized and effective novel kinase inhibitors that systemic exposure with the aim of reducing side effects. minimize CompanyThe is working to is developed for the treatment of glaucoma. AMA0076, lead candidate, Amakem’s Action platform to a range of eye diseases. apply the Localized Drug a highly potent Rho Kinase (ROCK) inhibitor targeted at the treatment of glaucoma, AMA0076 is a novel, has been designed to allow forAMA0076 high condition resulting in vision loss and ultimately blindness. resulting in a lack of side effects. localized dosing in the eyesystemic exposure, combined with low to be highlyAMA0076 has been shown in a number of models effective in reducing intraocular pressure (IOP), AMA0076 has also been by increasing outflow through the trabecular meshwork. a major factor in glaucoma, shown to avoid important side effects hyperemia which is distressing for such as patients and has been a dose ‘red eye’ results from excess hyperemia Also known as limiting factor for other ROCK inhibitors in development. blood flow in vessels in the white of the eye. the Company is exploring the development As well as glaucoma, primary focus is on eye diseases. Amakem’s of additional compounds targeting other eye and has collaborations diseases with amongst others the Ophthalmology other ophthalmic indications. Leuven Hospital (ULH) on several Research Center of the University Amakem has demonstrated models of proof-of-concept in advanced AMA0076 in glaucoma, In addition to Chronic Obstructive Pulmonary Disease (COPD) and asthma. Belgium. Amakem was founded Diepenbeek, in 2010 and is based in MANAGEMENT Senior Management CEO Jack Elands, CSO Dirk Leysen, Board of Directors chairman Michael Palfreyman, (Forbion) Takke, Christina Agricole) (Crédit Emmanuelle Coutanceau, (Vesalius) Gaston Matthyssens, (LRM) Vandervelpen, Nico Jack Elands Dirk Leysen Scientific Advisors University Hospital Leuven Ingeborg Stalmans, Thrombogenics founder Désiré Collen, Gary Novack Eric Sheinin Bob Osterberg Thomas Brown YEAR FOUNDED 2010 EMAIL [email protected] FAX +32 11 490-209 TELEPHONE +32 474 828-580 ADDRESS Amakem NV BioVille A bis Agoralaan B-3590 Diepenbeek, Belgium CONTACTS Dr Jack Elands Chief Executive Officer Dr Dirk Leysen Chief Scientific Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

1.4 17.9 2010 (19.1)

0.3 22.6 2009 (17.2)

ANY PROFILE

COMP of human gene based therapies. is a leader in the development Amsterdam, founded based in in 1998 and AMT, company the has been able to design and as the delivery of choice for vehicle therapeutic genes, AAV Using This safe and efficacious production platform. AAV validate what is probably the first stable and scalable proprietary platform offers a unique manufacturing capability which can be applied to a large number of rare AAV- with several AMT has a product pipeline Currently, (orphan) diseases that are caused by gene. one faulty Disease Acute Intermittent Porphyria and Parkinson’s DMD, Hemophilia B, based gene therapy products in LPLD, at different stages of research or development. AMT has established a safe and effective delivery gene approach that and a unique process enables the powerful platformThis combined commercially scalable manufacturing of gene therapy products. economical, to deliver more AMT with exciting opportunities with the research expertise of our collaboration partners provides curative therapies to patients faster MANAGEMENT CEO Aldag, Jorn Cash Net Result Income AMT (Amsterdam Molecular Therapeutics) Molecular (Amsterdam AMT www.amtbiopharma.com FINANCIAL SUMMARY € M YEAR FOUNDED 1998 EMAIL [email protected] [email protected] FAX +31 20 566 7292 TELEPHONE +31 20 566 8014 ADDRESS AMT Meibergdreef 61 Amsterdam 1105 BA CONTACT Aldag Jorn Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

20+ years global clinical development and management experience CEO • LS Pharma International, CEO • Hesperion, Clinical Director • Hoffmann-La Roche, patents experience and start-up immunology, 20+ years biology, CSO/COO Anergis, • CSO • Dictagène, Assist Professor University Lausanne • 20+ years medical practice and research in immunology and allergy Allergy/Immunology and Chief Prof. Assoc. • • Lausanne University Hospital (CHUV) Anergis • Founder of MSc MBA Insead, • Business and Finance consultant AG • Director Finance Kuros Biosurgery VI Partners • Investment and finance manager, management pharma business and commercial 20+ years biotech, Managing Director • IDEFI Gestion, GM & CEO • Stallergenes, Head Pharma Division • Eli Lilly France, Anergis SA Anergis www.anergis.ch FINANCIAL SUMMARY CHF 18M round March 2011. PROFILE COMPANY biopharmaceutical companyANERGIS SA is a Swiss-based specializing in the discovery and development Allergy is the “desensitization”) products. or “SIT” immunotherapyof novel ultra-fast specific (also known as growingmost prevalent and the fastest million with over 300 world chronic condition in the industrialized SIT remains underused due to its long duration Current (3-5 years of treatment) and safety people affected. can achieve induction which SIT treatmentsANERGIS develops ultra-fast and safe for allergic patients, risks. know-how and the exclusive ANERGIS possesses a unique of tolerance to the allergen in few injections only. rights to the technology of Contiguous Overlapping Peptides (“COPs”) developed jointly by the University of Hospitalier Universitaire (EPFL) and the Centre Technology of the Federal Institute Switzerland (UNIL), Lausanne, ANERGIS COPs are long peptides they present the advantage of being recognized Because (CHUV). Vaudois and processed by mechanisms as the originalof the immune system using similar the antigen presenting cells combined with the fact that the COPs reproduce –in separate molecules- the full amino This feature, allergen. and that overlapping sequences guarantee that are present, all linear epitopes acid sequence of the allergen, ANERGIS has studied proprietary COPs In the past years, ensures the high immunogenicity of the COPs. These studies have confirmed the targeting bee venom and birch pollen allergies both in animals and in humans. excellent safety (no immediate allergic and expected immunogenicity (production of specific antibodies reaction) ANERGIS COPs. and cytokines against the original allergen) of MANAGEMENT CEO Vincent Charlon, CSO Christophe Reymond, Medical Expert François Spertini, Finance Director Zoltan Czigler, Business Development Jean-Paul Rohmer, YEAR FOUNDED 2001 EMAIL [email protected] FAX +41 21 651 9221 TELEPHONE +41 21 651 9220 ADDRESS BioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland CONTACT Vincent Charlon PhD, CEO Zoltan Czigler MBA, Finance Director WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Highlights:

Randomized, active controlled Phase III trial (SAPPHIRE) with trabedersen open for of patients recruitment with Randomized, anaplastic astrocytoma and secondary glioblastoma. Encouraging survival and excellent safety of trabedersen in pancreaticand malignant melanoma in Phase cancer I/II trial.. MANAGEMENT Officer Acting Chief Executive Officer and Chief Medical Dr Hubert Heinrichs, Antisense Pharma GmbH Pharma Antisense www.antisense-pharma.com FINANCIAL SUMMARY Asset Fund in 2011. round with MIG Fonds and GA Global Successful closing of financing PROFILE COMPANY Germany. companyAntisense Pharma is a biopharmaceutical located in Regensburg, The company focuses its innovative strength on targeted cancer immunotherapies and is dedicated drugs based on a powerful gene silencing technologyto discovering and developing for worldwide The pipeline comprises the lead product trabedersen in clinical development for high-grade commercialization. pancreatic carcinoma and malignant melanoma as well as drug candidates in discovery and preclinical glioma, development for cancer and other indications. (AP 12009) specifically the synthesis of the human transforming inhibits growth factor beta 2 Trabedersen a multifunctional cytokine promoting tumor malignancy via multiple mechanisms. (TGFß2), portfolioAntisense Pharma has a solid and long-lasting IP of grantedpatents in all major markets. The EMA and the FDA have granted trabedersen an orphan drug status for high-grade glioma and pancreatic carcinoma. Recent YEAR FOUNDED 1998 EMAIL [email protected] FAX +49 941 92013 29 TELEPHONE +49 941 92013 0 ADDRESS 9 Josef-Engert-Str. 93053 Regensburg Germany CONTACTS Auerbach Dr Guenter Head Business Operations Theoharis Dr Stefanos Senior Director Corporate Research Development & External WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

More than 20 years in R&D management at Sandoz/Novartis; Founded and developed the biotech company Igeneon (cancer public relations. R&D strategy, business strategy, Main responsibilities: immunotherapy). PhD in Biochemistry and Biotechnology from the University of Natural Resources and COO, Manfred Schuster, Vienna. Applied Life Sciences in Main as scientist and project leader at Igeneon. Worked Vienna; Started his career at the Novartis Research Institute, cooperations. infrastructure, IT, IP, QM, clinical research, responsibilities: Vienna University of Economics and Business. graduate degree in Commerce from CFO, Lukas Kadawy, human resources, investor relations, legal, finance, Main responsibilities: Apeiron. He has worked at IBM prior to joining administration. APEIRON Biologics AG Biologics APEIRON www.apeiron-biologics.com FINANCIAL SUMMARY Private company. PROFILE COMPANY is a biotech company a focus with on biological and immunological Austria, Vienna, based in Apeiron, Apeiron presently innovative On top of an preclinical pipeline, approaches to treatcancer and related conditions. strategy business is to generate value Apeiron’s project and three projects in phase II. has one clincal phase III primary customers Apeiron’s by applying of concept. to advance projects towards clinical proof its know-how however, In certain cases, in the relevant disease areas. include all pharmaceutical/biotech companies active Apeiron may complete all development stages and market the final product directly. MANAGEMENT Vienna. CEO, PhD in Organic Chemistry from the University of Hans Loibner, YEAR FOUNDED 2003 (operational since 2006) EMAIL [email protected] FAX +43 1 8656577-800 TELEPHONE +43 1 8656577 ADDRESS AG APEIRON Biologics Campus-Vienna-Biocenter 5 Vienna, 1030 Austria CONTACTS PhD Hans Loibner, Chief Executive Officer Mag. Lukas Kadawy, Chief Financial Officer PhD Manfred Schuster, Chief Operating Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

APEPTICO GmbH APEPTICO www.apeptico.com FINANCIAL SUMMARY 0.5 Million Pre-seed EURO 2008: 3.5 Million A EURO Round 2009: 3.5 Million Round B EURO 2010: PROFILE COMPANY develop new peptide-based medicinal We Austria. Vienna, APEPTICO is a clinical stage biotech company in peptide molecules correspond to validated, Our drugs for the clinical treatment of severe and chronic diseases. All our of well-known proteins and biopharmaceuticals. pharmacodynamic active structures and domains products address highly profitable and markets. growing biological & medical databiopharmaceuticals of well-characterised proteins and structural, molecular, collect We Identification of a bio-active moiety is the first step of in our proprietary data base PEPBASE(TM). our fast-track product development pathway. PEPSCREEN(TM), The applications in combination PEPSCREEN(TM) and PEPBASE(TM) with our cumulated Research & and Development experience enables to create compounds which allow for novel intellectual property protection, at reduced costs and decreased business risks. facilitates lower clinical failure rates, AP301 is water and can be soluble AP301 family are synthetic peptides. lead molecules of the APEPTICO’s AP301 can be nebulised and the Formulated administered into the lung by instillation or by oral inhalation. AP301 was originally designed resulting aerosol is composed of peptide/water droplets of diameter 3 µm or less. Additional research demonstrated for the treatment of acute lung injury and acute respiratory distress syndrome. such as prevention and treatment AP301 has additional significant potential in related clinical indications, that prevention of progression of acute hypoxemic pulmonaryof edematous respiratory permeability edema, failure, AP301 respiratory injury. failure due to bacterial / viral pneumonia and prevention of ischemia reperfusion activates lung edema reabsorption cells from influenza virus-, both endothelial and epithelial lung and protects of lung and reactive oxygen species-induced lung edema and hyper-permeability microbial virulence factor- capillaries. MANAGEMENT CEO Dr Bernhard Fischer, CSO Prof Dr Rudolf Lucas, YEAR FOUNDED 2008 EMAIL [email protected] FAX +43 1 25330337795 TELEPHONE +43 664 1432919 ADDRESS APEPTICO GmbH c/o mino bueros 136 Mariahilferstr. Vienna 1150 Austria CONTACT Fischer Bernhard Dr. Univ.-Doz. CEO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u APRI 22M* 16M* ~$5M 19.6M* $5.26** ~320k** $10.2M* ~$105M**

p

t: t: y-diluted Shs: ve. Daily volume ve. 2010 Revenues PROFILE COMPANY has leveraged the a San Diego based revenue-generating specialty pharmaceutical company, Apricus Bio, flexibility of its clinically-validated drug delivery NexACT® technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Revenues and growth of this technology are driven from out-licensing for the development and In addition, commercialization and biotechnology of such compounds to pharmaceutical companies worldwide. approved Vitaros®, including its first product, the Company product pipeline, is seeking to monetize its existing which is currently expected to be available on the Canadian in Canada for the treatment of erectile dysfunction, currently focused on III, as well as compounds in development from pre-clinical through Phase market in 2011, Diabetes and Cosmeceuticals Anti-Infectives, Pain, Autoimmune, Dermatology, Oncology, Sexual Dysfunction, among others. MANAGEMENT President and Chief Executive Officer Chairman, Bassam Damaj, Dr. Vice President and Chief Financial Officer Senior Steve Martin, Vice Corporate Development and Investor Relations Edward Cox, and Secretary General Counsel Vice President, Randy Berholtz, Executive Shares Out: Floa Cash position Marketca A 2011 **As of June 24, 2011, *As of March 31, Apricus Biosciences, Inc. Biosciences, Apricus www.apricusbio.com Full Share-price FINANCIAL SUMMARY NASDAQ: YEAR FOUNDED 1987 EMAIL [email protected] [email protected] TELEPHONE Dr Bassam Damaj +858-222-8041 Ed Cox +858-222-8041 ADDRESS Suite 103 6330 Nancy Ridge Dr., CA 92121 San Diego, U.S.A. CONTACTS Dr Bassam Damaj CEO President & Chairman, Ed Cox VP Corporate & IR Development WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u biocrea Gmbh biocrea www.biocrea.com FINANCIAL SUMMARY minority stake. which has a Therapies, by initial funding Biotie Private Company, PROFILE COMPANY Therapies The company is an MBO from Biotie biocrea is creating therapies new for debilitating CNS Diseases. Pharma and corporate from large finance biocrea strives Team a new ManagementWith 2010). (Nov. Corp. will fund its VC funding and through development to major value inflection points to acquire projects and their discovery through non-dilutive funds. activities Wyeth have a proven track record to turn concepts into candidate drugs and have been partnering with GSK, We and Pfizer. MANAGEMENT Kronbach, Chief Executive Officer Tom Chief Scientific Officer Martin Gunthorpe, Chief Financial Officer Viehweg, Viktor Vice President Chemistry& Development Executive Ward, Simon YEAR FOUNDED 2010 EMAIL [email protected] [email protected] [email protected] FAX +49 351 4043 3216 TELEPHONE +49 351 4043 0 PhD Kronbach, Tom +49 351 4043 3332 Viehweg Viktor +49 351 4043 0 ADDRESS Bio3 Research S.r.l. Via della Moscova 6/8 20121 Milano Italy CONTACTS PhD Kronbach, Tom CEO Viehweg Viktor CFO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Biotie Therapies Corp. Therapies Biotie www.biotie.com FINANCIAL SUMMARY (EUR 11.6 30 June 2011 million on and short term investments totaled EUR 40.9 Cash and cash equivalents The groups’ strengthened financial position had been by a private placement of EUR million on 30 June 2010). and by27 million in March 2011 in February the liquid assets of Synosia acquired 2011. PROFILE COMPANY clinically Biotie is an international biopharmaceutical company focused development of innovative, on the differentiated to address unmet medical needs primarily medicines associated with neurological and psychiatric We aim to develop treatments that will improve the lives of diseases and with selected inflammatory diseases. drug dependency and inflammatory liver diseases, Alzheimer’s and patients with conditions such as Parkinson’s diseases. Our highly Europe and the US are focused experienced development teams in on efficiently delivering safety For niche indications Biotie will consider bringing products to the market and efficacy data for our compounds. For larger indications we will seek strategic partners for partnerships with pharmaceutical late-stage by itself. UCB Roche, Our current pharmaceutical partners include Lundbeck, development and commercialization. Pharma and Seikagaku Corporation. has completed Phase 3 clinical development nalmefene for alcohol dependence, most advanced product, Biotie’s A/S. Lundbeck by licensing partner H. MANAGEMENT President and CEO Veromaa, Timo Chief Medical Officer Stephen Bandak, Chief Operating Officer Ian Massey, Chief Business Officer Chris Piggott, Chief Financial Officer Ulla Sjöblom, YEAR FOUNDED 1992 EMAIL [email protected] TELEPHONE +358 2 274 8900 ADDRESS Biocity 6 Tykistökatu Turku FIN-20520 Finland CONTACTS Virve Nurmi Head of Investor Relations Veromaa Timo Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u Previously CFO of SantoSolve, responsible for raising three financing rounds, and supporting the company and supporting from preclinical responsible for raising three financing rounds, Previously CFO of SantoSolve, banking sector. He has extensive experience from the Nordic investment stage until phase III. COO Thorfinn Ege, Previously business development and management in the pharmaceutical sector. Ege has extensive experience in research, from the early project preclinical stage to phase III. the company’s advancing AS, CEO in SantoSolve CSO Sergio Lociuro, Arpida Ltd (Head of research) and from and in drug discovery, Lociuo has more than 20 years experience in antiinfectives He is author of numerous publications and holds several patents. positions in MMD and GSK. executive mgmt. C10 Pharma AS AS Pharma C10 www.c10pharma.com PROFILE COMPANY C10 PHARMA is a Norwegian company focusing of a new family on the development of antibiotics in the macrolide class. The basis for strategy the development is proprietary technology relating to post-synthetic modifications of the 14-membered macrolide molecules. carbon-10 side chain in The company that has shown chemical modifications of the macrolide ring can be used to build in this position ADMET properties. molecules with highlyattractive antimicrobial and based on structure-guided drug design. The company is currently in the lead generation phase of the project, data are very promising – showing that unprecedented structural the carbon-10 can be used to allow Test ADME(T) characteristics. both building attractive antimicrobial activity and modulating key modifications, and the company planning to raise funding is The company expects to enter lead optimization phase late 2011, in the companyThe main investors are Novo Seed (Denmark) and Sarsia Seed sometime during 1H:2012. (Norway). MANAGEMENT CEO Vaage, Torgeir YEAR FOUNDED 2009 EMAIL [email protected] [email protected] [email protected] TELEPHONE +47-92405235 ADDRESS AS C10 Pharma Drammensveien 41 0271 Oslo Norway CONTACTS Vaage Torgeir CEO Thorfinn Ege COO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u Caldera Health Limited Health Caldera www.calderahealth.com FINANCIAL SUMMARY the Company was awarded 2010, June, In a seed investment of NZ$560,000. Caldera completed 2010, In May, Technology. and Science Growth Grant from the New Zealand Foundationa NZ$189,000 Business of Research, A second research grant NZ$987,500. raising a first round of equity funding, 2011 Caldera completed In May, applicationway. is on its PROFILE COMPANY It is developing human in vitro Diagnostics (IVD) company. Auckland-based, an Caldera Health Limited is superior to the globally used sophisticated molecular diagnostic devices for early detection of prostate cancer, The diagnostics PSA test by improving reliability and indicating the long-term outcome of any cancer detected. today not possible because of the will allow extensive monitoring of tailored treatments for prostate cancer, limited molecular diagnostic tools available. MANAGEMENT Chief Executive Officer PhD, Watson, James D. Chief Science Officer PhD, Forster, Richard L.S. VP Business Development PhD, Toder, Roland YEAR FOUNDED 2009 EMAIL [email protected] FAX +64-9-571 0316 TELEPHONE +64-9-571 0310 ADDRESS Caldera Health Limited, 11664, P.O.Box Auckland 1542, Ellerslie, New Zealand CONTACT PhD Toder, Roland Vice President Business Development WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Can-Fite has license agreements with Seikagaku Corporation (Japan) and Kwang Dong (Korea). MANAGEMENT Ph.D., Chief Executive Officer Pnina Fishman, COO & Financial Director Motti Farbstein, VP Business Development Barak Singer, Can-Fite BioPharma, Ltd. BioPharma, Can-Fite www.canfite.com FINANCIAL SUMMARY Stock Aviv Tel public offerings on the Can-Fite has raised till today approximatelyfunding, $60M from venture and from strategic partners. Exchange (TASE) PROFILE COMPANY companyCan-Fite is an Israeli biopharmaceutical Phase 3 and with a rich pipeline of small molecule drugs in A3 adenosine The platform technology utilizes the Gi protein associated stages. Phase 2 clinical development The company has diverse pipeline of proprietary compounds, a biologicalreceptor as a target and marker. All company drugs are orally bioavailable with an liver diseases. ophthalmic and addressing inflammatory, excellent safety profile. of matter, protecting the composition 100 individual cases, Can-Fite intellectual property includes more than The company has 43 publications in peer reviewed scientific clinical applications and way of synthesis matters. journals. Pipeline: YEAR FOUNDED 2001 EMAIL [email protected] FAX +972-3-924 9378 TELEPHONE +972-3-924 1114 ADDRESS 10 Bareket Street, Kiryat Matalon 7537, P.O.Box 49170, Tikva Petach Israel CONTACTS Ph.D Pnina Fishman, Chief Executive Officer Barak Singer VP Business Development WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

CELL MED Research GmbH MED Research CELL www.cellmed.at FINANCIAL SUMMARY Company EUR 9.3 million for already raised the project development. required to fund the next milestones in the clinical EUR 7 million investment PROFILE COMPANY is a CMO (Contract Manufactoring Organisation)CELL MED Research GmbH running a GMP (Good capital, Austrian near to the approvedManufacturing Practice) laboratory site in Krems/Donau, and production Vienna. MANAGEMENT Chief Executive Officer Huber, Wolfgang Dr YEAR FOUNDED 2006 EMAIL [email protected] FAX +43 2732 70512-50 TELEPHONE +43 2732 70512-0 ADDRESS Magnesitstraße 1 3502 Krems Lerchenfeld Austria CONTACTS Huber Wolfgang Dr Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

CerMed International CerMed www.cermedcorp.com COMPANY PROFILE COMPANY CerMed International is a medical device company (FSE:CRX) thatserves global billion dollar markets supporting The Company will launch contraception. HIV protection and health needs in cervical cancer detection, women’s in Q4 2011 under cervical first combined and mapping specimen collection system, the world’s CerMap, These will be distributed initially in Diagnostics. Audit a $20m contract for cervical screening systems with CerMark is being developed as the Additionally, Asia and Eastern Europe. China then other key across markets break through technologyThis is a major advance only point-of-care cervical cancer screening device. world’s affordability and usability for which significantlyeffectiveness, improves the over current screening processes, especially in CerMark will facilitate the early detection and treatment globally, of women patients and clinicians. will begin a drug eluting cervical cap barrier contraceptive, CerCap, In September 2011, developing countries. CerCap enables women clinical trials supported by the University of California and the University of Zimbabwe. managementprovides team CerMed’s risk of HIV infection. control in preventing pregnancy and reducing the and managingextensive expertise in life sciences and in building companies. successful MANAGEMENT CEO Peter Gombrich, CFO II, Jones, Wendell Jimmy Lee Ken Holbrook Robryt Regan Mary Ruberry YEAR FOUNDED 2008 EMAIL [email protected] [email protected] caroline.bergmann @mc-services.eu FAX +1-831-920-2276 TELEPHONE +1-831-920-2275 Caroline Bergmann AG MC Services +49-89-210228-20 ADDRESS CerMed International 2511 Garden Road, Suite B100 Monterey CA 93940 USA CONTACTS Steve Roon Caroline Bergmann AG MC Services WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Cevec Pharmaceuticals GmbH Pharmaceuticals Cevec www.cevec.com FINANCIAL SUMMARY Since late successfully 2008 CEVEC markets its cell based technology for protein and antibody production. Most recently an EUR venture capital venture rounds up to now. in several The company has attracted 10 Mio. include Lead investors investors. over 6 Mio EUR could be closed with their existing additional venture round and NRW.Bank. Venture Creathor PROFILE COMPANY business case: vaccine The CAP CEVEC commercializes of an innovative platform technology for the production of vaccines and biopharmaceuticals in human cell lines. CEVECs CAP cells hold high promise for production system for as best-in-class Influenza vaccines and other Compared to leading other cellular production systems (like as shown by a recent case study. virusal vaccines, minimal and cycles production short extreme yield, virus of demonstratedview CAP in MDCK) results outstanding CEVECs CAP system is suspension based and serum free offering the best starting point for media consumption. Being the only independent remaining new vaccine production approaches upscaling possibilites. with excellent recently the company sets out to repeat the growth story of Crucell B.V., supplier for human production cell lines, acquired by Johnson & Johnson for 2.4 Bn US$. Feasibility studies demonstrated CAP being a versatile virus production platform with the broadest possible RSV, Commercially include hCMV, significant targets array of human viruses potentially replicating on them. 3 lead projects have been identified Lentiviruses and others. Adenoviruses, AAV, Measles, Polio, Influenza, Vaccine Project together with its partner the first human platform for hCMV, including and planned, Germany. Hannover, Manager, of this investment Aim EUR venture round. 7-10 Mio. CEVEC heads out in 2nd half of 2011 to raise another I results and hCMV influenza and RSV within 3 years to clinical phase will be to push the vaccine lead projects, manage technology a broad roll-out of its vaccine production to maximize its company in order exit value by low-risk and high return in an exciting New venture investors are now invited to participate 2015. growth story. www.cevec.com please visit: For further information, MANAGEMENT CEO Dr Rainer Lichtenberger, Managing Director/CCO Kintzel, Wolfgang CSO Dr Gudrun Schiedner, VP Development & Services Dr Nicole Faust, America VP BD North Gary Boch, Asia BD Europe & Dir. Tintrup, Dr Hartmut YEAR FOUNDED 2001 EMAIL [email protected] FAX +49 221 460208 01 TELEPHONE +49 221 460208 00 ADDRESS 62 Gottfried-Hagen-Str. 51105 Koeln CONTACT Dr Rainer Lichtenberger Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

ChromaCon AG ChromaCon www.chromacon.ch FINANCIAL SUMMARY ChromaCon has been profitable since inception. PROFILE COMPANY companyAG is a biopharmaceutical that markets enabling develops and bioprocess solutions for the ChromaCon It also collaboratesthe development of biopharmaceutical projects. with partners in biopharmaceutical industry. best-in-class technology platform enables (Contichrom™) the development of Its patent-protected, previously novel biological not accessible with improved characteristics medicines and life cycle products the the enabling Besides features, PEGylated proteins. glycosylation variants, such as bispecifics antibodies, Contichrom™ platform and COGs by allows to reduce CAPEX up to 50% for the production of biologics. and on commanding through distribution partners business model is based on equipment sales ChromaCon’s license fees on production equipment use. MANAGEMENT CEO Guido Stroehlein, CBO Michael Bavand, CSO Thomas Müller-Späth, CTO Aumann, Lars YEAR FOUNDED 2007 EMAIL [email protected] [email protected] TELEPHONE +41-44-445 20 10 ADDRESS 1 Technoparkstr. 8005 Zuerich Switzerland CONTACT MBA PhD Guido Stroehlein, CEO PhD Michael Bavand, CBO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Covagen AG Covagen www.covagen.com FINANCIAL SUMMARY Seroba Kernel Life Ventech, Edmond de Rothschild Investment Partners, Fund, Venture Novartis Investors: Management. Venture MP Healthcare Sciences, PROFILE COMPANY Switzerland) is pioneering the commercialization of bispecific and multivalent Covagen (Zurich-Schlieren, innovative of action for mechanisms the treatment of next generation drugs (Fynomers) with novel, protein readily Fynomers can be fused to antibodies which results in bispecific inflammatory diseases and cancer. Fynomers Furthermore, fusions with increased potency and novel mechanisms of action. Fynomer-antibody which allow for can be assembled in a modular manner to createmultivalent Fynomers, bispecific as well as treatment modalities that with antibodies. cannot to be exploited TECHNOLOGY small binding proteins (7 kDa) derived from the fully human SH3 domain of the Fyn kinase. Fynomers are novel, to their Due Fynomers can be engineered to bind to anytarget of interest with high affinity and specificity. which results Fynomers can be fused to the CH3 domain of full-size antibodies, favorable biophysical properties, Covagen is in bispecific biopharmaceuticals with increased therapeutic new mechanisms of action. efficacy and TNF/IL-17A inhibitor. developing a bispecific MANAGEMENT Board of Directors Executive Chairman Walsh, Frank Ray Hill Franz Hefti Anja König Gilles Nobécourt Karl Naegler Jon Hepple Julian Bertschinger Scientific Advisory Board Ulrich Feige Thierry Hercend Christoph Heusser Christoph Lengauer YEAR FOUNDED 2007 EMAIL [email protected] FAX +41 44 732 46 64 TELEPHONE +41 44 732 46 60 ADDRESS AG Covagen 25 Wagistrasse 8952 Schlieren, Switzerland CONTACTS Dr Julian Bertschinger Chief Executive Officer Dr Dragan Grabulovski Chief Scientific Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u borations markets as well as distribution partnerships and R&D colla markets as well as distribution partnerships and R&D

model:

Product company – medical devices, molecular diagnostics Product company – medical devices, Expect a mix of direct product sales in home Curetis AG Curetis www.curetis.com FINANCIAL SUMMARY ZIM) to A round; several German research grants (e.g. Series € raised in seed round and of over 27 million Total co-fund certain R&D projects. investors: Venture as KfW. as well CD-Venture, BioMed Partners, Partners), LSP (Life Science aeris CAPITAL, PROFILE COMPANY Business as well as commercialization alliances. Technologies/Targets: Unyvero hardware platform and disposable cartridge-based molecular diagnostic system with integrated sample First indication pathogen detection and antibiotic array multiplex PCR and detection. DNA purification, prep, resistance detection in pneumonia. Status: Start of pivotal clinical studies forplanned for EU and USA 2011; Expected product launch in EU in 2012. MANAGEMENT CEO Oliver Schacht, Managing Director R&D Andreas Boos, Managing Director Operations Johannes Bacher, Affairs Director Marketing & Medical Thews, Anne Director Bio-Assay Development Gerd Luedke, Dr. CFO Anne Burger, YEAR FOUNDED 2007 EMAIL [email protected] FAX +49-7031-49195-12 TELEPHONE +49-7031-49195-12 +49-173-2147112 ADDRESS AG Curetis 42 Max-Eyth-Str. 71088 Holzgerlingen Germany CONTACT Oliver Schacht Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

$ 6.5 million $26.5 million $42.5 million

ANY PROFILE Series B Series C COMP private company and developing small molecule drugs designing is a clinical-stage, Cylene Pharmaceuticals CK2-dependent pathways leadership in exploiting enables the Cylene’s against newly validated cancer targets. creation of first-in-class Phase II and CX-8184 in preclinical development) thatagents (CX-4945 in serve as the drug of choice in rational drug combinations for improved treatment outcomes against many cancer indications. RNA Polymerase I (Pol l) Inhibitor program delivers first-in-class targeted agents (CX-5461 The Company’s approaching Phase I) that non-genotoxic pathway act through the ideal for activating p53 to kill cancer cells. unique approach delivers innovative agents that enable pharmaceutical companies to expand their Cylene’s lifecycle and reach of current cancer therapeutics. portfolios and extend the efficacy, approach to exploiting newly validated and key targets signaling pathways has created a pipeline of Cylene’s knowledge unique mechanistic created in-house through Cylene’s These molecules, targeted cancer agents. by are supported an extensive intellectual property portfolio including 121 pending and chemistry expertise, managementThe team has the experience and talent to deliver these new applications and 26 issued patents. execution, record of creativity, The company’s agents as pharmaceutical drugs to patients to the market. and frugality and pipeline creation have enabled Cylene to attract corporate and traditional venture capital investors This solid foundation to deliver innovative positions Cylene drugs that will fulfill the unmet medical needs of alike. cancer patients and their families. MANAGEMENT President and Chief Executive Officer Ph.D, Rice, William G. Affairs Medical Vice President, Co-founder and F.A.C.P., M.D., Hoff, Von Daniel D. Affairs Clinical and Regulatory VP, Senior Pharm.D., Lim, John K.C. Chemistry and Pharmaceutical Ops VP, Senior Ph.D, Ryckman, David M. Cylene Pharmaceuticals, Inc. Pharmaceuticals, Cylene www.cylenepharma.com FINANCIAL SUMMARY A Series YEAR FOUNDED 2001 EMAIL [email protected] [email protected] [email protected] FAX + 1-858-875-5101 TELEPHONE +1-858-875-5100 ADDRESS 5820 Nancy Ridge Drive Suite 200 San Diego 92121 CA, USA CONTACTS Ph.D. Rice, William G. Officer President & Chief Executive Ph.D. O’Brien, Sean E. Alicea Irene WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

DC Prime www.dcprime.com PROFILE COMPANY DCPrime is a clinical stage Dutch biotech company a unique platform which has developed technology, and a proprietary“DCOne™”) method to expand consisting of sustainable dendritic progenitor cells (named this generates with cancer antigens, Upon loading these and to create mature functional dendritic cells (DCs). with great advantages DC over current dendritic cell-based therapeutic products, off-the-shelf, standardized, vaccines. Amsterdam, Center (VUmc) in VU University Medical a spin-off (DCPrime) is company of the DCPrime B.V. Dr. companyThe was founded in 2005 by Prof. dedicated a novel type of therapeutic to developing vaccines. Rik Scheper. Dr. Ada Kruisbeek and Prof. It has become clear that sometimes produce spectacular results in individual patients. DC-based vaccines can they pose significant logistical and however, Since DC-based vaccines are based on patient-derived DC, DCPrime is creating a new type of DC-based vaccines that bypass the problems standardization problems. associated with patient-derived DC vaccines. Unique Features standardized product) DC-based immunotherapy. DCPrime is the first to test an allogeneic (non-patient-derived, This DC from this line. and the processes to produce DCOne, This is based on its proprietary progenitor DC line, with the power of DC and stimulationshould combine the expected superior allogeneic system, of the immune Such a standardized product is much more attractive from a production, off-the-shelf product characteristics. it concerns a technology platform that allows for different Moreover, operational and clinical perspective. DCOne cell line is an DCPrime’s As such, each tailored to a specific kind of cancer. products to be made, immunotherapy platform applicable in a broad range of cancer types. MANAGEMENT Kruisbeek, CEO & CSO Ada M. YEAR FOUNDED 2005 EMAIL [email protected] [email protected] FAX +31 20 59 89 904 TELEPHONE +31 20 59 89 905 ADDRESS De Boelelaan 1085 – F546 Amsterdam 1081 HV The Netherlands CONTACTS Kruisbeek Ada M. Prof Dr CEO & CSO Aniek Büller Assistant to professor Kruisbeek WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Delenex Therapeutics AG Therapeutics Delenex www.delenex.com FINANCIAL SUMMARY completed in MayA round financing 2011; 30.2 MCHF. Series PROFILE COMPANY It is AG is a clinical stage Swiss biotechnology company established in September 2009. Therapeutics Delenex focussing of therapeutic on the development antibody fragments. VCs and one new already invested A round financing from be raised in a Series 30.2 MCHF could Recently, Ventures). VC firm (Novo leading validated platform PENTRA® to develop best-in-class antibody fragments for Delenex uses its proprietary, solubilities Its PENTRA® technology rapidly produces drug-like fragments that affinities, exhibit highest therapy. With initial focus on dermatological and CNS disorders and stabilities with a very low risk of immunogenicity. COGS as well local and topical applications of bacterially expressed antibody fragments are investigated to limit i. side effects observable systemic administration after of antibodies. as ii. Delenex has assembled an internationally team with lots of years of experience gained in both the recognized For more details please It operates out of laboratories and offices in Schlieren/Zürich. pharma and biotech world. review the company website www.delenex.com.. MANAGEMENT Chief Executive Officer Dr Eric de La Fortelle, Chief Scientific Officer Kretzschmar, Titus Dr Chief Finance Officer Mr Jakob Schlapbach, Chief Medical Officer Thomas Jung, Dr YEAR FOUNDED 2009 EMAIL [email protected] FAX +41 (0) 44-7305-181 TELEPHONE +41 (0) 44-7305-180 ADDRESS AG Therapeutics Delenex 27 Wagistrasse CH-8952 Schlieren Switzerland CONTACT Kretzschmar Titus Dr Chief Scientific Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

EnVivo Pharmaceuticals EnVivo www.envivopharma.com PROFILE COMPANY is a biopharmaceutical company dedicated USA, Massachusetts, Watertown, located in EnVivo Pharmaceuticals, with an small molecule therapeuticsto discovering and developing for disorders of the central nervous system, lead product EVP- The company’s cognition disorders and Schizophrenia. disease, Alzheimer’s emphasis on acetylcholine receptor agonist6124 is an alpha-7 nicotinic for being tested in Phase 2b clinical trials cognition Phase 2b trial was recentlyThe schizophrenia completed and Schizophrenia. disease Alzheimer’s impairment in to havein which EVP-6124 proved a positive effect and negative on both the cognitive symptoms as well as Another clinical program epigenetics approach is based on an using EVP-0334 as a functional performance. Histone Deacetylase inhibitor (HDACi) for improvement and disease modification cognition in several orphan a Gamma Secretase Modulator in Phase I as a the company testing EVP-0962, is In addition, indications. a PDE10 inhibitor in IND-enabling disease and has EVP-6308, Alzheimer’s potential disease modifying agent in studies for the positive symptoms of Schizophrenia. The company currently its main investor is Fidelity Biosciences. employs 45 people and MANAGEMENT CEO Kees Been, SVP Finance and CFO Stephen DiPalma, SVP Clinical Development and CMO MD, Dana Hilt, SVP Research and CSO PhD, Gerhard Koenig, General Counsel Maiken Keson, VP HR Elaine Ouellette, YEAR FOUNDED 2001 EMAIL [email protected] TELEPHONE +1 - 617-225 4210 ADDRESS Arsenal Street 480 MA 02472 Watertown, USA CONTACTS Kees Been Maiken Keson WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Epigenomics AG Epigenomics www.epigenomics.com FINANCIAL SUMMARY For ISIN DE000A1K0516). (ECX, Standard: Prime Epigenomics is publicly listed at the Frankfurt Stock Exchange, website. financial information please refer to the Investor Relationsof the Company’s section PROFILE COMPANY diagnosticsEpigenomics is a molecular company a pipeline of proprietary developing and commercializing products enable diagnose doctors to cancer earlier and more accurately, The Company’s products for cancer. is a blood-based test Epi proColon®, Epigenomics’ lead product, forleading to improved outcomes patients. which is currently is in development for marketed in Europe and the for the early detection of colorectal cancer, technology have and products been validated through multiple partnerships with leading The Company’s U.S.A. Epigenomics is an and Quest Diagnostics. Sysmex, QIAGEN, Abbott, global diagnostic companies including international . MANAGEMENT Epigenomics is lead by a highly skilled and motivated management team of executives and senior vice and Europe. presidents with track records in the industry in the U.S. Beckmann Coulter) and Dako, Abbott, Nygaard (formerly Walther The team is headed by CEO Geert Burrill & Company). Venture, Deutsche Therapies, (formerly Biotie Taapken Thomas CFO Dr. CEO Nygaard, Walther Geert CFO Taapken, Thomas Dr YEAR FOUNDED 1998 EMAIL [email protected] FAX +49 30 24 34 5 555 TELEPHONE +49 30 24 34 5 0 ADDRESS AG Epigenomics 1 Kleine Präsidentenstr. 10178 Berlin Germany CONTACT Antje Zeise WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

f-star GmbH f-star www.f-star.com PROFILE COMPANY f-star is a next generation antibody company developing improved therapeutic antibodies and antibody Technology. Antibody fragments unique Modular based on its and antibody binding sites into antibodies allows the introduction of additional Technology Antibody Modular Antibody Using Modular fragments by engineering the non-CDR loops of constant or variable domains. antibody fragments small sized (Fcab™) with full antibody functionality or full length antibodies with Technology, can be created.additional functionality (mAb²) Company the currently highly employs more than twenty qualified people at its research Founded in 2006, the Company is supported by pioneers in the Advisory Board, In its UK. Austria and Cambridge, Vienna, sites in Anthony Rees and Sir Prof. including Sir Ravinderresearch and development of monoclonal antibodies Maini, Winter. Gregory covering management team has many in the biotech and pharmaceutical industry, years of experience f-star’s and finance. business development intellectual property, pharmaceutical development, antibody engineering, Aescap world-class f-star enjoys the strong financial support from a science investors including group of life TVM Capital. A/S and Novo Venture, Atlas Venture, MANAGEMENT Chief Executive Officer Dr Kevin FitzGerald, Chief Scientific Officer Dr Kevin Moulder, YEAR FOUNDED 2006 EMAIL [email protected] FAX +44 (0)1223 896351 TELEPHONE +44 (0)1223 896350 ADDRESS Granta Park Abington Great Cambridge CB21 6GS UK WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Faron Pharmaceuticals Ltd Pharmaceuticals Faron www.faronpharmaceuticals.com FINANCIAL SUMMARY private equity and technology and institutional loans. Operations funded from revenues, Private company. PROFILE COMPANY is a privately owned clinical stage discovery drug and development company in Faron Pharmaceutical Ltd. inflammatory projects focusing Faron has three major drug development on acute trauma, Today Finland. Turku, lead product FP-1201 has successfully passed a phase I/II study in the Faron’s spreading. and cancer diseases, Faron is currently expanding the FP-1201 programa pan- to ALI/ARDS patients. UK to treat vascular leakage in The primary efficacy endpoint European pivotal phase III study that company hopes to get started in H2-2012. which decreased below 10 % in the above mentioned phase II in this study will be all cause mortality at day 28, study from commonly observed 35-40 %. MANAGEMENT Very seasoned life science managers above) (see contacts with significant experience from early drug company Large network of world-class pharma experts support operations. development coordinate operations. Faron Board consists of two lawyerspharma experts. and three YEAR FOUNDED 2007 EMAIL markku.jalkanen @faronpharmaceuticals.com ilse.piippo @faronpharmaceuticals.com mikael.maksimow @faronpharmaceuticals.com FAX +358-2-469-5153 TELEPHONE +358-40-520-6124 +358-400-222-407 +358-50-330-8333 ADDRESS 6 B Tykistökatu Turku FIN-20520 Finland CONTACTS Dr Markku Jalkanen Chief Executive Officer Dr Ilse Piippo VP Drug Development Dr Mikael Maksimow Research Director WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u continued...

Galantos Pharma GmbH Pharma Galantos www.galantos.com FINANCIAL SUMMARY rounds and grants€ 9 million in three investment PROFILE COMPANY Introduction is a biopharmaceutical companyGalantos Pharma GmbH developing innovative drugs for treatment the of its focus of marketed drugs and natural is on the improvement At present, neurodegenerative diseases. Disease (AD). Alzheimer’s substances for the treatment of Alfred Maelicke (Mainz) and Ulrich Jordis (Vienna) as a spin-off of The company was founded in 2005 by Profs. Memogain, Germany. Laboratory of Molecular Neurobiology at the University of Mainz Medical School, Maelicke’s symptomatic is scheduled to move into clinical trials in 2011 and has shown potent its most advanced product, improvement and plaque reduction in animal models. disease in Alzheimer’s Long-standing expertise AD and The founders of Galantos Pharma GmbH have a long-standing experience in the neurochemistery of laboratory Maelicke’s AD. have to reduce cognitive impairment in been proponents of galantamine as a drug AD is accompanied byacetylcholine receptors a severe loss of nicotinic that among others, demonstrated, It later identified a novel class of nAChR ligands capable of remaining nAChRs, of enhancing the activity (nAChR). which provide a very safe mechanism for symptomatic the so-called allosteric potentiating ligands (APLs), improvement and disease modification. Pipeline Currently a very safe and potent derivative of galantamine. The lead product of Galantos Pharma is Memogain, Galantos’ AD and lost patent in 2009. protection galantamine is arguably the best marketed treatment for offers It improved Memogain is an inactive prodrug effectivelydelivering active galantamine into the brain. Preclinical investigations have demonstrated potency for improved effectiveness at much reduced toxicity. GLP toxicity has formation in a mouse model. Alzheimer-plaque symptomatic improvements and reduced I will start in the second quarter of this year. Clinical phase demonstrated very low toxicity. Clinical development is largely supported bythe fact that Memogain is completely metabolized to the pharmacologically active compound which approved since 2000. nicotinic acetylcholine compounds (APLs) targeting the Galantos is exploring novel neuroprotective In addition, APLs receptors. receptors in general (nAChRs) and a subtype-specific enhancers of nicotinic acetylcholine AD. provide a very the sensitivity of receptors that safe mechanism to enhance are progressively lost during Results in animal models indicate that enhancing the sensitivity of nAChRs has considerable therapeutic AD and other CNS-related diseases. potential in Commercialization Strategy Galantos’ strategy is to achieve a fast and rewarding return of investment for its first project and to co-fund development of the research funded earlier pipeline. phase I this year and license the drug to a pharma The Company clinical will bring Memogain into aims Galantos For the earlier stage pipeline, development and marketing. partner for later clinical and attrition rate of to form strategic alliances with pharma partners to reduce development costs creating a revenue stream. medication candidates, Alzheimer’s YEAR FOUNDED 2005 EMAIL [email protected] [email protected] [email protected] FAX +49 6131 1440-329 TELEPHONE +49 6131 1440-311 ADDRESS Galantos Pharma GmbH Freiligrathstraße 12 55131 Mainz CONTACTS Sandra Gerdemann Jutta Blesius WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

, CFO, Karl Krista, Dr med. He has 19 years of international industrial experience financing and commercialization. Responsible for financial planning, former CEO of CellControl and Senior Engagement Manager at McKinsey. including: Head of R&D Kaletta, Titus Dr Department Head at Devgen. incl. Has more than 10 years of relevant industry experience, Applied Chemical Synthesis atProf Dr Ulrich Jordis, co-founder of the company Laboratory and Head of the of Vienna. University of Technical the Key founder and Head of R&D of the company. He was Professor of Biochemistry He was Professor at and Department Head the Medical Faculty Key founder and Head of R&D of the company. where he focused molecular and cellular aspects of development and degeneration on in the human of the University of Mainz, he founded Genetics and Galantos Pharma and Galantos In 2005, disease. Alzheimer’s drug development for and on brain, programsince then headed the R&D of Galantos Pharma. CBO Andreas Köpke, Dr Dr Köpke has 10 years of international academic and operations of the company. Responsible for business development, as Head of Business research and 15 years of management experience in the pharmaceutical and biotech industry: Janssen Transfer Technology Associate Director of Collaboration & Proteomics) and CEO (WITA Development Pharma (Devgen), initiated and closed more than 20 important deals, Pharmaceutica (Johnson & Johnson) he has created effective departments, he became acquainted with While working at Janssen, an IPO and a company and took part in sale. led merger discussions, galantamine and Prof Maelicke. Galantos Pharma GmbH Pharma Galantos www.galantos.com ...continued MANAGEMENT CSO Alfred Maelicke, Prof Dr YEAR FOUNDED 2005 EMAIL [email protected] [email protected] [email protected] FAX +49 6131 1440-329 TELEPHONE +49 6131 1440-311 ADDRESS Galantos Pharma GmbH Freiligrathstraße 12 55131 Mainz CONTACTS Sandra Gerdemann Jutta Blesius WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

GlycoVaxyn AG GlycoVaxyn www.glycovaxyn.com FINANCIAL SUMMARY VCs including and B from blue-chip European A the company has raised CHF 37.5 million in series So far, and Edmond de Rothschild Investment Partners. Ventures Index Sofinnova Partners, PROFILE COMPANY private bio-pharmaceutical company and developing vaccines to designing is a clinical-stage, GlycoVaxyn was founded in 2004 GlycoVaxyn in prevention of bacterial diseases worldwide. address unmet medical needs (ETHZ) to develop and commercialise of Zurich Technology Federal Institute of as a spin-out of the Swiss and currently is based in Switzerland, GlycoVaxyn applications of its proprietary bioconjugation technology. employs 38 people. MANAGEMENT CEO Philippe Dro, CSO Wacker, Michael YEAR FOUNDED 2004 EMAIL [email protected] FAX +41 44 733 85 74 TELEPHONE +41 44 733 85 85 ADDRESS GlycoVaxyn Grabenstrasse 3 8952 Schlieren Switzerland CONTACT Arena Angela Assistant Executive WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

ocused on single GPCR target of strategic greement with Shire (2011) for novel small molecule adensoine A2A antagonist with greement with Shire (2011) for adensoine novel small molecule tely $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to Takeda tely $100 million drug discovery collaboration with -year collaboration with AstraZeneca (2011) focusedantibody on developing small molecule and -year collaboration with Four Exclusive option a (2009) f $200 million alliance with the Novartis Option Fund Novartis and Heptares jointly announced the successful first-ever stabilisation of this interest to Novartis. previously intractable technology. GPCR using the Heptares  CV/metabolic and inflammatory disorders. candidatesCNS/pain, targeting specific GPCRs linked to  is the first-ever GPCR this our knowledge, To best-in-class potential for the treatment diseases. of CNS candidate to arise solely from SBDD. CNS disorders. Approxima • • • • MANAGEMENT Co-Founder and Chief Executive Officer Weir, Dr Malcolm Co-Founder and Chief Scientific Officer ` Dr Fiona Marshall, Chief Business Officer Dr Barry Kenny, Heptares Therapeutics Ltd Therapeutics Heptares www.heptares.com FINANCIAL SUMMARY Novartis Option Fund and MVM Life Science Partners, Ventures, date$40M venture finance to from Clarus Ventures. Takeda PROFILE COMPANY Heptares is a drug discovery company creating targeting G-protein-coupled receptors (GPCRs). new medicines The Company is currently leveraging its GPCR expertise and proprietary technology StaR® to build a pipeline metabolic and other GPCR-targeted medicines of best-in-class and first-in-class for the treatment of CNS, diseases. due to their inherent yet, GPCRs represent the single most important family of drug targets in the human body, little or no structural information about these valuable targets instability when removed from cell membranes, Heptares’ StaR® (Stabilised has been available discovery to drive structure-based drug (SBDD) programmes. This breakthrough allows Heptares Receptor) technology enablesthermo-stabilisation the first-ever of GPCRs. structure-based drug discoveryscientists to resolve GPCR structures and deploy techniques to identify potent and selective drug candidates to previously undruggable targets. YEAR FOUNDED 2007 EMAIL [email protected] TELEPHONE +44 1707 358 629 +44 7968 947 268 ADDRESS Therapeutics Ltd Heptares BioPark Broadwater Road Garden City Welwyn AL7 3AX Hertfordshire CONTACT Weir Malcolm Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

immatics biotechnologies GmbH biotechnologies immatics www.immatics.com FINANCIAL SUMMARY A total of € 108m raised. concluded. Three financing rounds PROFILE COMPANY immatics that is developing cancer vaccines help to activate of the human body. the self defense mechanisms Our goal is to support patients and physicians with new options in the fight against various cancers. immune peptides thatOur means are synthetic specifically activate white blood cells of the patient’s specialized system against cells. cancer MANAGEMENT Chief Executive Officer Paul Higham, Chief Scientific Officer Dr Harpreet Singh, Chief Medical Officer Dr Carsten Reinhardt, YEAR FOUNDED 2000 EMAIL [email protected] FAX +49 7071 5397 900 TELEPHONE +49 7071 5397 100 ADDRESS immatics biotechnologies GmbH Paul-Ehrlich-Straße 15 Tuebingen 72076 Germany CONTACT Mark Bleckmann Director & Head of Finance WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Immune Targeting Systems Targeting Immune www.its-innovation.com FINANCIAL SUMMARY The company nearly has raised and series-A (2007 / 2010) from Blue chip £14.5m of funding via a seed (2004) Technologyand Esperante the London Capital, Truffle HealthCap, Fund, Venture investors including the Novartis Agency. £0.5m grantThis funding also included from the London Development funding Ventures. PROFILE COMPANY Systems (ITS) is London based Biotech Company for developing vaccines mutating viruses Targeting Immune a synthetic ITS’ lead program, and Densigen™ technology platforms. underpinned by its DepoVaccine™ is currently flu strains, all potential seasonal and pandemic universal influenza vaccine (Flunisyn™) targeting Flunisyn™ clinical data highlights it is safe and well tolerated and completing phase-I clinical testing. T-cell vaccine class potential and validates this unique approach to vaccine immunology data confirms its best in A phase-II efficacy study will initiate in 2011. design. injection site depot deliver Densigens™ to the immune system promoting a short-term vaccine DepoVaccines delivered Densigens™ DepoVaccine™ immunity. T-cell durable and recallable antiviral to promote potent, contain multiple different rationally long peptide antigen sequences (35aa) which are conjugated selected to This yields a thermostable freeze dried nanoparticle formulation when formulated. a fluorocarbon molecule. selection focuses antigen on selecting highly conservedVaccine antigens (cross strain/genotype) to ensure a response which is capablepopulation of providing broad coverage and a vaccine responder frequency T-cell exceeding a multi-peptide breadth of response selection, targeting >90% without restrictive HLA sub-type vaccines are Synthetic peptide based current best-in-class and a potent-durable magnitude of response. without responses upon revaccination, T-cell well suited for chronic disease treatment they because boost requiring heterologous prime-boost strategies using a second vaccine technology (contrast DNA & viral vector technologies). in addition to Influenza-A. cancers, HCV, represent an ideal immunotherapy platform forDepoVaccines™ HBV, [email protected] Contact: ITS welcomes partnering discussions. MANAGEMENT Carlton Brown, Chief Executive Officer R&D Director Ph.D, Campbell Bunce, Finance Director Cowper, Tim Officer Technical Chief Ph.D, Bertrand Georges, Manufacture Vaccine Head of Ph.D, Jill Makin, YEAR FOUNDED 2003 EMAIL [email protected] [email protected] TELEPHONE +44 20 7691 4908 ADDRESS Systems Targeting Immune (ITS) Ltd c/o London Bioscience Innovation Centre 2 Royal College Street London NW1 0NH United Kingdom CONTACT Carlton Brown Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Dr. Horn (Presently Head of Novel Biologics, NsGene) did his undergraduate studies at University of Southern Denmark Horn (Presently Head of Novel Biologics, Dr. The work performed in Japan (1993-1996). Technology Institute of Tokyo (1989-1993) and spent the following 3 years at UK at Repair the Brain a year at Horn then spent Cambridge University, Dr. earned him a Master of Biotechnology degree. Dr. From 1997 to 2006, degreeCentre which was concluded with a Master of Philosophy in Neuroscience (1996-1997). a short stay Horn had at Dr. In 2007, Aarhus University where he earned a PhD degree in Medicine. Horn was associated with Statens Serum Institute before being recruited to NsGene to head the factor discovery program which eventually became the Horn has been responsible for developing these programs at NsGene in close collaboration with Dr. novel biologics program. Denmark and he has more than University, Technical including Søren Brunak and his group at the Danish academic groups, Horn has authored more than a Dr. 10 years experience in bridging gap the between bioinformatics and experimental biology. book chapters and patent applications. dozen scientific publications, Ingentyx www.ingentyx.com FINANCIAL SUMMARY 5 million to € totaling milestone-driven tranche-released equity finance Ingentyx is aiming to raise approx. launch and run the company for 3 years; enabling of new biological the development drugs for the treatment evaluation and is to fund our discovery, The principal objective of the financing of immunological diseases. including in vivo studies with established prime candidates animal models and testing of development activities, property the intellectual and expanding Ingentyx will furthermore invest in maintaining with patient materials. rights protecting mainly its biological products but also technologies. PROFILE COMPANY Intomics and Celentyx are NsGene and Celentyx. Ingentyx is based on the combined expertise of Intomics, currently using their state-of-the-art and technologies facilities as CROs for major pharmaceutical companies with a major biotechnologyand NsGene has entered a multimillion dollar contract company for one of its therapeutic proteins. evaluate and develop we will be able to discover, into Ingentyx, By combining the activities of these 3 companies new therapeutic candidates for the treatment of immune related diseases. In 2012 we expect to establish 5 new potentially therapeutic candidates for comprehensive immuno-profiling. In 2013 we expect to file at least one patent application for a novel therapeutic protein and we expect to have whereafter a strategic alliance or an M&A are out-licensed at least 2 therapeutic proteins by the end of 2014, very realistic options. Ingentyx has a clear exit strategy in the form of an M&A. MANAGEMENT Chief Executive Officer Ph.D, Per Horn, YEAR FOUNDED Primo 2012 (expected) EMAIL [email protected] TELEPHONE +45 2081 5802 (mobile) ADDRESS Baltorpvej 154 2750 Ballerup Denmark CONTACT Ph.D Per Horn, Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

InteRNA Technologies B.V. Technologies InteRNA www.interna-technologies.com FINANCIAL SUMMARY Seed. PROFILE COMPANY is a Dutch early stage drug discovery and development company mission to with the Technologies InteRNA With its proprietary miRNA lentiviral-based develop miRNA-based pathway targeted therapeutics for cancer. expression library (the largest currently available) takes a unique holistic R&D approach InteRNA and focuses on the demonstrationindications function of its miRNAs in a number of cancer of the screens. through functional provide a steady basis which This approach results in the rapid identification of multiple novel drug candidates, collection of novel InteRNA has exclusive IP rights to a vast for further validation and clinical drug development. to technologies for identification detection of miRNAs and and miRNA sequences (not in public domain/miRbase), to diagnostic and therapeutic miRNAs in disease. uses of certain MANAGEMENT CEO MBA, PhD, Schaapveld, Roel Q.J. CDO PhD, Grégoire Prevost, YEAR FOUNDED 2006 EMAIL schaapveld @interna-technologies.com FAX +31 30 253 9176 TELEPHONE +31 30 253 2386 ADDRESS Kruyt building Hugo R. Padualaan 8 3584CH Utrecht Netherlands CONTACT Schaapveld Roel Q.J. Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Invetech www.invetech.ch PROFILE COMPANY custom automation and contract Invetech is a global innovator in instrument and new product development, discovery. medical devices and drug cell therapy, experience in diagnostics, manufacturing with extensive engineering and with specialist expertise in innovative design, Invetech has a staff more than 200, of processes are certified and our quality system and development are ISO 9001:2008 We manufacturing. Automated (Quality System Regulation)compliant with FDA QSR for and with GAMP (Good biomedical products facilities are ISO13485:2003 certified, Our manufacturing forManufacturing Process) custom automation. bioMérieux and Abbott, supported by as clients such and audits with world leading biomedical regular reviews Bio-Rad. MANAGEMENT to the Danaher groupInvetech is part of Leica Microsystems which belongs of companies. YEAR FOUNDED 1988 EMAIL [email protected] FAX +41 44 536 0412 TELEPHONE +41 78 881 0376 ADDRESS Industriestrasse 25 (Zurich) Volketswil 8604 Switzerland CONTACTS PhD Andreas Koch, PhD Aigner, Peter WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

ISA Pharmaceuticals BV ISA Pharmaceuticals www.isa-pharma.com FINANCIAL SUMMARY Fundraising series B. PROFILE COMPANY clinical stageISA Pharmaceuticals is a company developing novel therapeutic products for cancer and infectious its proprietary ISA exploits SLP® technologyachieve therapeutic to effects in a number of indications. diseases. under development is a therapeuticThe most advanced product SLP-HPV® vaccine for the treatment of patients Virus type 16 (HPV16) associated (pre-) malignant disorders. sufferingPapilloma from Human MANAGEMENT CEO Gerard Platenburg, CSO Cornelis Melief, CMO Johan Frieling, YEAR FOUNDED 2004 EMAIL [email protected] FAX +31 (0) 71 3322311 TELEPHONE +31 (0) 71 3322310 ADDRESS ISA Pharmaceuticals BV Niels Bohrweg 11-13 2333 CA Leiden The Netherlands CONTACT Vogelezang Maaike Assistant Management WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Ph.D., President & CEO Ph.D., anagement Dr. Kim founded LSKB as a business development and regulatory consulting firm. He has over 20 years experience in the Kim founded and regulatory LSKB as a business development consulting firm. Dr. manufacturing, cGMP clinical trials, preclinical studies, pharmaceutical industry as product development, covering areas such He also held principal researcher DDS company. a US-based VP of Samyang Research Corporation, He was Korean and US RA. His positions in R&D at Samyang Corporation he was instrumental in developing two successful oncology where products. in B.S. an M.S in Pharmaceutics and a Sungkyunkwan University, Pharmaceutics, in academic experience includes a Ph.D. Pharmacy from Sungkyunkwan University. Vice President Executive M.A., Kim, Alex S. Kim has 20 years Mr. to the Board of Directors. he was elected In December of 2007, Kim joined LSKB in May of 2007. Mr. (now Inc. VivoRx, Inc.; Plc); Expression Genetics, (now BTG, Inc. experience in the pharmaceutical industry at MacroMed, experience at these companies includes Kim’s Mr. Pharmaceuticals). Watson Theratech (now Abraxis Pharmaceuticals); He strategic and M&A activity. planning product and technology licensing, business development, executive management, Japan and Bachelors Degree Tokyo, received his Masters Degree in International Business from Sophia (Sang Ji) University in from the University of Utah. Sung Chul Kim, LSK BioPharma www.lskbiopharma.com FINANCIAL SUMMARY Private Corporation. PROFILE COMPANY drug development company“LSKB”) is a US-based managed by (dba LSK BioPharma, Inc. LSK BioPartners, The Company industry who have experts next-generation a successful track record of developing cancer drugs. YN968D1 (apatinib mesylate), entity rights (excluding China) to the new chemical has the exclusive worldwide Phase This drug has completed Advenchen Laboratories in California. originally and developed by synthesized Metastatic Breast Advanced Gastric Cancer, in patients1/2/3 clinical trials in China and is being studied with which has a global market potential of almost $2.5 YN968D1, Advanced Hepatocellular Carcinoma. Cancer and is expected to receive market approval in China by late 2011. Billion, in JulyLSKB completed a Pre-IND meeting with the US FDA intends to file an IND in the third of 2011 and The Company funding for has secured non-clinical and clinical trials through a non-dilutive quarter of 2011. LSKB management Asian pharma company. a major global co-development deal with Bukwang Pharma, forecasts a cash needs of about to support internal operations $1.4 million and milestone payments through The Company intends to raise this YN968D1 is expected to be in Phase 2 clinical trials. the end of 2013 when milestones are met. amount in 2 tranches over the next two years as YN968D1 to a major pharmaceutical company for pivotal trials and The Company intends to sell or outlicense through earlyYN968D1 With the successful development of marketing during the US Phase II clinical trials. LSKB intends to continue leveraging area of its expertise in the niche development clinical trials in the US, preclinical to early clinical trials by new opportunities. in-licensing M YEAR FOUNDED 1995 EMAIL [email protected] FAX +1(801) 303 7455 TELEPHONE +1(801) 303 7440 ADDRESS 8 East Broadway Suite 611 Salt Lake City Utah 84111 USA CONTACTS Alex Kim Vice President Executive WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

orce.

0 rant for Bladder cancer 1,968 6,812 7,439 10,532 10,593 - 8,366 16 million EUR

tion/data of prostate products

ted y raised 8,2 million EUR

blish its own US-based CLIA certified laboratory

– 1,1 million $ new g – Clinical valida – New partnering deals with big pharma – Esta – Start recruiting a US based sale f – Compan – Cash on hand :

 ting costs



COMPANY PROFILE COMPANY MDxHealth is a leading molecular diagnostics company that develops and commercializes molecular diagnostic numerous cancer tests are based on proprietary gene The company’s products for personalized medicine. and of recurrence risk, prognosis methylation technology with the diagnosis and assist physicians of cancer, MDxHealth collaborates center with leading cancer research prediction of response to a specific therapy. Virginia Eastern Respiratory Lovelace Research Institute, Duke University, such as Johns Hopkins University, medical centers. and major European academic Sloan Kettering, Memorial Cleveland Clinic, Medical School, Merck & Co./Schering The company collaborative has a number of commercial and partnerships with LabCorp, industry Pfizer and other leaders. Qiagen, Merck KGaA, Roche, GlaxoSmithKline Biologicals, Plough, MANAGEMENT Senior Management CEO Dr Jan Groen, CFO Mr Philip Devine, Technology VP Sciences & Criekinge, Van Wim Prof. Affairs VP Legal Mr Joseph Sollee, Affairs & Quality VP Reg. Thompson, Dr Melissa VP R & D Dr James Clark, Operations Lab. Sr Dir. Mrs Miriam Reyes, Operations Thibodeau,VP Com. Mr Christopher Board of Directors/Affiliation Edmond de Rothschild Investment Partners Wisniewski, Mr Raphaël Independent Dr Karin Dorrepaal, Independent Windels, Mrs Hilde Independent Mr Mark Myslinski, Independent Mr Edward Erickson, Gengest BVBA Mr Rudi Mariën, MDxHealth Dr Jan Groen, Scientific Advisory Board Prof Jonathan Epstein Prof James Herman Prof Gerrit Meijer Wallen Dr Eric Outlook Cash burn MDxHealth SA MDxHealth www.mdxhealth.com FINANCIAL SUMMARY EUR ‘000 December 2010 in Commercial revenues Opera Of which are R&D rela EBIT Cash in hand Financial debt Q2 YEAR FOUNDED 2003 EMAIL [email protected] [email protected] FAX +32 4 364 20 84 TELEPHONE +32 4 364 20 70 ADDRESS MDxHealth SA 11 l’Hôpital, de Avenue Giga + 3 Tour 4000 LIEGE, BELGIUM CONTACTS Dr Jan Groen Chief Executive Officer Mr Philip Devine Chief Finance Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

$30 $1,000 $4,100 $12,200 Premarket

pital:

Assets: y Burn: ANY PROFILE

Dr. Satya Prakash, PhD (Biomedical Engineering), Director and Co-founder PhD (Biomedical Engineering), Satya Prakash, Dr. expert in bacteria as therapeutics and professor of biomedical engineering at McGill University, Co-founder of Micropharma, on the topic. and author of three books listed as an inventor in 27 patents, articles, 150 peer-reviewed delivery technologies, Ten year track record of success in raising capital, business development, and management of life science companies business development, year track record of success in raising capital, Ten Development Bus. MBA, Dir. MD, Wahl, Chris Dr. Medical Products Practice as a consultant to Pharmaceutical, in the Pharmaceutical and Medical at McKinsey and Co. Worked expert in worked at Frosst Canada in the Patient Merck Health Management Group, Device and Biotechnology companies, and commercialization. reimbursement, regulatory, strategy, CSO MD and PhD (Biomedical Engineering), Mitchell Jones, Dr. expert in inventor of all relevant Micropharma technology including Cardioviva™ and ProSelect, Co-founder of Micropharma, expert in clinical medicine. product discovery and development, Current The Company as biotherapeuticsMicropharma Limited discovers and develops bacteria for metabolic diseases. uses its proprietary discovery and development platform ProSelect to screen and select bacteria with interesting Micropharma then phenotypic traits that target metabolic pathways recognized as having therapeutic potential. The uses its novel fermentation and optimizationtechniques to over express desirable traits of the organism. first the world’s Company has proven the effectiveness by of ProSelect successfully developing Cardioviva™, ProSelect to develop Micropharma is using and therapeutic bacteria product. biomarker linked, disease-specific, Micropharma or biotherapeutic products. a pipeline of candidates as over-the-counter to out-license or partner forhas one market-ready product LrC (Cardioviva™) hypercholesterolemia and two products underdevelopment La101 for and chronic liver disease (CLD) and minimal hepatic Lr54 for type two diabetes, including, Cardioviva™ is a highly proved safe and bile-salt-hydrolase (BSH) active bacteria which encephalopathy (MHE). reducing Cardioviva™ works by deconjugating bile, effective at study. lowering LDL-C in a proof-of-concept A second proof-of- and increasing catabolism and excretion of cholesterol. dietary absorption of cholesterol, Our two unpartnered preclinical formulationconcept study using a BSH-optimized Cardioviva™ is ongoing. and is proving to be Lr54 was selected and optimized to produce a unique set of proteins products include: increased highly effective for treatment diabetes of type two working through a combination of anti-inflammation, gut bacteria in the gut, decreases urease producing La101, and decreased glucose uptake. glucose metabolism, and has a very unique bioavailable polyphenolic acid fingerprint in blood leading to increased ammonia porosity, oxygen and nitrogen species and reducing reactive decreasing endotoxins, reduced inflammation, detoxification, in blood. MANAGEMENT CEO BEng, Ryan Jones, Revenue: Monthl Previous Ca COMP Micropharma Limited Micropharma www.micropharma.net FINANCIAL SUMMARY Stage: YEAR FOUNDED 2003 EMAIL [email protected] [email protected] FAX 514 987-4616 TELEPHONE 514 977 3000 Ryan Jones 514 987 4151 Wahl Dr Chris 514 987 4151 x3 ADDRESS President Kennedy Ave. 141 5th Floor UQAM – Biological Sciences Building Unit 5569 Montreal Quebec Canada H2X 3Y7 CONTACTS Ryan Jones Chief Executive Officer Wahl Chris Dr. Director of Business Development WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Molecular Partners AG Partners Molecular www.molecularpartners.com FINANCIAL SUMMARY CHF18.5m A (July 2007): Series CHF46m Series B (Dec 2009): Corporation • Johnson & Johnson Development Ventures • Index Ventures Health Woodlands Essex Investors: Vision • Endeavour Ventures • BB Biotech PROFILE COMPANY that is Switzerland, located in Zurich, Molecular Partners is a privately owned biopharmaceutical company, DARPins are protein therapeuticspioneering the development of a novel class of targeted termed DARPins. they overcome the known being small proteins, Yet, as target specific and potent as monoclonal antibodies. and develop address real medical needs We limitations of conventional protein-based therapeutic approaches. cutting-edge medicine based on innovative products. DARPin The most advanced The DARPin platform has rapidly generated a differentiated pipeline of drug candidates. which has completed two separate Phase I/IIa clinical trials in VEGF antagonist, a long acting DARPin is MP0112, the most common causes AMD) and diabetic macular edema (DME), wet age-related macular degeneration (wet for vision loss. $375 million for $45 million up-front payment, Allergan Inc. MP0112 was out-licensed to In May 2011, regulatory milestones and tiered double-digit and sales royalties on any future sales of MP0112. development, inflammation and and lateFurther compounds are in preclinical development stage in oncology, research ophthalmology. with major several DARPins are being developed in partnership In addition to our fully owned drug candidates, biopharmaceutical companies. Molecular Partners is backed by a very strong international syndicate and corporate of institutional investors. MANAGEMENT CEO Dr Christian Zahnd, CSO Dr Michael Stumpp, Amstutz, CBO Dr Patrick CFO Andreas Emmenegger, YEAR FOUNDED 2004 EMAIL [email protected] FAX +41 44 755 7707 TELEPHONE +41 44 755 7700 ADDRESS AG Molecular Partners 14 Wagistrasse 8952 Zürich-Schlieren Switzerland CONTACTS Dr Christian Zahnd Chief Executive Officer Andreas Emmenegger Chief Financial Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

4.062% 4.062% 7.107% 4.297% 2.493% 23.941% 10.488% 43.549%

t)

Assurance SA

ARK RAF SpA

FININVEST SpA SCIENCE P H-Equity Srl H-Invest SpA Airain Lda Delfin Sàrl Lombard Int. Others (free floa

, a novel vascular targeting agent, in Phase III for in Phase malignant pleural mesothelioma and in Phase II a novel vascular targeting agent, , a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III for a cell-based therapy enabling transplants from partially bone marrow compatible donors, ANY PROFILE  NGR-hTNF liver and ovarian cancer. non-small-cell lung, small-cell lung, colorectal, in six other types of solid tumours: high-risk leukaemia; TK, • • MolMed S.p.A. MolMed www.molmed.com FINANCIAL SUMMARY at the Standard segment (class I) of 2008, Milan Stock Exchange since March 5, listed on the Public company, managed by. Borsa Italiana the MTA with gross of € 57.8M. proceeds August 2010, Share capital completed in increase € 122.4M. Market Cap (07/07/11): Shareholders (21/06/2011):

COMP development and clinical validation is a biotechnology company established focused on research, MolMed S.p.A. of novel anticancer therapies. both in Phase III : pipeline includes two investigational therapeutics, MolMed’s Italy. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, class I) of the MTA Stock Exchange (Standard segment, MolMed shares (Milan:MLM) are listed on the Milan managed by Borsa Italiana. MANAGEMENT Senior Management: CEO Claudio Bordignon, Administration General Manager Business & Marina Del Bue, General Manager R&D and Operations Germano Carganico, Board of Directors: Chairman Claudio Bordignon, Luigi Berlusconi Silvio Bianchi Martini, Lead independent director Renato Botti Maurizio Carfagna Castelli Paolo M. Independent Riccardo Cortese, Executive Director Marina Del Bue, Independent Alessandro De Nicola, Massimiliano Frank Sabina Grossi Alfredo Messina Tassi Maurizio Scientific Advisory Board: Chairman Claudio Bordignon, Carl-Henrik Heldin Robet Kerbel Alberto Sobrero Trono Didier YEAR FOUNDED 1996 EMAIL [email protected] [email protected] FAX +39 02 21277 325 TELEPHONE +39 02 21277 1 ADDRESS MolMed S.p.A. via Olgettina 58 Milan 20132 Italy CONTACT Holger Neecke Director Business Development and Investor Relations WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Mucosis B.V. Mucosis www.mucosis.com FINANCIAL SUMMARY €3,000,000 (2007) A: Series €3,000,000 (2010) Inn.Credit: NOM • MedSciences Capital • N.V. Ventures Biogeneration Current Investors: PROFILE COMPANY About Mucosis on which it Mimopath™, is a Dutch biotechnology company with a proprietary platform technology, Mucosis B.V. a vaccine to prevent lead products are FluGEM™, Mucosis’s develops mucosal vaccines with improved efficacy. a a vaccine to prevent diseases caused SynGEM™, by pneumococcal bacteria; and influenza; PneuGEM™, Mimopath™-based in the vaccines can be administered needle-free vaccine to prevent RSV viral infections. evoking a more natural immune response with a broader base of protection. nose and mouth, About Mimopath™ technology a safe bacterium commonly used in the food The Mimopath™ technology lactis, is based on Lactococcus lactis bacteria into non-living bacterium- to formulate Mucosis has developed a robust technique the L. industry. The antigen- parasitic or tumor origin. bacterial, like particles (BLPs) that from viral, can be loaded with antigens These for without the need a needle. covered BLPs form a vaccine that into the nose or mouth, can be delivered vaccines raise protective immunity by activation of both the innate and the adaptive immune system. MANAGEMENT Senior Management Chief Executive Officer Govert Schouten, CSO Kees Leenhouts, CBO Thomas Johnston, CMO Roberto Grimaldi, QA-officer & Qualified Person Jolande Schoemaker, Board of Directors Chairman John Lambert, Barry Buckland Wouterse Annemieke Willem Hazenberg Otto Postma YEAR FOUNDED 2006 EMAIL [email protected] FAX +31 (50) 8200051 TELEPHONE +31 (50) 8200050 (T) +31 (6) 55320948 (M) ADDRESS Mucosis B.V. Zielstraweg 1 L.J. Groningen 9713 GX, The Netherlands CONTACT Dr Govert Schouten Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Mymetics Corporation Mymetics www.mymetics.com FINANCIAL SUMMARY stageMymetics is a development company and has not generated significant revenues until now. The company mainly has been financed though private a mixture of equity and convertible debt. HNWI through More info see SEC filings PROFILE COMPANY developing MYMX) BB: (OTC biotechnologyUS Swiss-based companythe registeredCorporationa in Mymetics is core technology Mymetics’ and expertise next-generation preventative vaccines for infectious diseases. in combination lipid-based carriers containing functional fusion viral proteins, are in the use of virosomes, vaccines are designed to induce protection against early The company’s with rationally designed antigens. which for some focusing defense, on the mucosal immune response as a first-line transmission and infection, Mymetics currently has 5 pathogens may be essential for of an effective the development prophylactic vaccine. The Virus. and Herpes Simplex Malaria Virus, Respiratory Syncytial Influenza, HIV-1/AIDS, vaccines in its pipeline: A Phase 1b clinical vaccine has completed a Phase I clinical trial in healthy human volunteers. HIV-1 company’s while RSV and HSV vaccine candidates has been completed, Tanzania trial for its Malaria vaccine on children in Abbott) vaccine has been out-licensed to SolvayThe Influenza Pharmaceuticals (now are in the preclinical phase. please visit www.mymetics.com For further information, and has successfully completed a Phase I. MANAGEMENT Chairman and CEO Jacques-François Martin, CSO Dr Sylvain Fleury, CFO & COO Ronald Kempers, YEAR FOUNDED 2001 EMAIL [email protected] FAX +41 21 653 2473 TELEPHONE +41 21 653 4535 ADDRESS Route de la Corniche 4 1066 Epalinges Switzerland CONTACT Ronald Kempers CFO & COO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

, CEO & Member of the Board ,

Ms. Orly Bar, VP Marketing Orly Bar, Ms. Bar has held several leading managerial and marketing positions both in healthcare organizations Ms. In the past 12 years, Tehcnion- as well as completing her Mathematics Studies in from the Oranim Institute, Orly holds a B.Ed. and HR companies. Technology. Israel Institute of . Vice President, R&D Vice President, Amir Katz, he Prior to joining the company, medical device systems to Neuronix. Amir brings extensive experience in the development of an MS in Biomedical in Mechanical Engineering, Amir holds a B.Sc. served as the R&D manager of a medical device company. Technology. Institute of Technion–Israel Engineering and an MBA from the Affairs Clinical and Regulatory Vice President, Alter, Ariela Dr. Ariela has servedAffairs in responsible for in senior positions Clinical & Regulatory In her career spanning over a decade, She has served as a managing clinical trials and designing regulatory worldwide strategy. several medical device companies, Pharmacology Surgeons of Columbia Department of the College of Physicians and York-Presbyterian Associate in the New Staff University and Tel-Aviv from an M.Sc. Technology, Institute of Technion-Israel in Biology from the Ariela holds a B.Sc. University. University. a PhD from Bar-Ilan CFO Haim Solovatzik, Overall Financial Management, Haim has over 20 years of experience with global high-tech corporations in the fields of: Activity. International Operations and Information Systems, Acquisitions, international and local Mergers & Tax, International and previously Finance manager in i-Sight (a Clal Director in Zoran Corporation, Tax Haim served as Finance and International from the Haifa University. Accounting (CPA) Haim holds a BA in Economics and Electronics Industries subsidiary). MANAGEMENT Eyal Baror A executive-level positions in several medical devices companies. Eyal brings over a decade of experience in R&D and in the Hebrew in Physics (cum-laude) from he holds a B.Sc. program, Talpiot graduate prestigious of the Israel Defense Force’s University Tel-Aviv in Physics (summa cum laude) from the and a M.Sc. University of Jerusalem, Neuronix Ltd Neuronix www.neuronixmedical.com FINANCIAL SUMMARY Company secured two grants In addition, US$ 5.5 M was invested in Neuronix. an amount of over As of today, amounting to 1.3MUSD. Office, from the Israeli Chief Science to enable completion of the US-FDA multi- additional round during the 2012 first half, Neuronix plans to raise an of its NeuroAD system in Europe. as well as marketing center study, PROFILE COMPANY quality of life formission is to provide long-term improvement in the patients with Neuronix’s Founded in 2008, an incurable and terminal disease affecting 26 million people worldwide. Disease (AD), Alzheimer’s disease. Alzheimer’s is the developer of the NeuroAD system for the treatment of mild to moderate Neuronix Ltd. the safe (NICE™) technology core Non Invasive Cortical Enhancer (patent pending), Based on the company’s to Training Magnetic Stimulation Cognitive (TMS) and targeted Transcranial non-invasive system integrates In first disease. Alzheimer’s in the specific regions of the brain affected by Potentiation (LTP) Term induce Long with NeuroAD has demonstrated the potential to slow down or stabilize progression, disease round of clinical, Further studies are currently underway in several results superior to those available medications. with current Offering a glimmer of hope and reprieve USA). medical centers around the globe (including Harvard University, statisticallyas well as pivotal studies. significant results were achieved on both pilot for sufferers and families, Alzheimer “treatment mild-moderate of The NICE™ technology has received CE approval for the indication of Patients. YEAR FOUNDED 2008 EMAIL [email protected] [email protected] FAX +972-4-9831938 TELEPHONE +972-4-9038600 Eyal Baror 972-54-4932572 Orly Bar 972-54-3221018 ADDRESS Yoqne’am POB 16 Israel 20692 CONTACTS Eyal Baror CEO Orly Bar VP Marketing WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

15 years of experience in preclinical and clinical development. CMO MD, Prof Ruggero Fariello, 30 years of clinical experience. Co-founder of Newron Pharmaceuticals, Head of Chemistry Dr Carlo Farina, 30 years of senior pharma experience. Founder of Nikem, Board of Directors founder of Prionics & Neurotune. BD&L, Chairman, Dr Bruno Oesch, 15 years experience in diagnosticdevelopment. Gerhard Musshafen 30 years of experience in management and marketing in the pharmaceutical and diagnostics industry. Dr Raimund Eckel 26 years of experience with strategic development in Boehringer Mannheim and Roche as well as executive management e.g. President of Boehringer Mannheim Japan. Neurotune AG Neurotune www.neurotune.com PROFILE COMPANY Swiss bio-pharmaceutical company founded in 2005 with currently 14 stage, AG is a clinical Neurotune companyThe is focusing on the discovery and employees at and Bioggio its Zurich sites in Switzerland. treatdevelopment of drugs to nervous disorders of the human peripheral and central system with an emphasis muscle on the modulation of synaptic pain and (2) age-related transmission in the treatmentchronic of (1) Both markets are commercially highly attractive. . loss (sarcopenia) up to phase II as well as diagnosticsNeurotune develops drugs to market. on sarcopenia focuses on the neurotrypsin/agrin unique approach which is key system in the Neurotune’s The company has a in particular at the neuromuscular junction (NMJ). build-up and modulation of synapses, CAF neurotrypsin inhibitors, therapeuticvery biologics, broad patent portfolio covering the neurotrypsin target, antibodies as well as animal models. based diagnostics, the neurotrypsin/agrin system offers large development potential as it playsBeyond an important sarcopenia, role in synaptic nervous plasticity in the central and peripheral system. has successfully completed safety and tolerability lead compound for neuropathic pain (NT-11624) Neurotune’s Follow-on compounds are under development at stage. preclinical endpoints (phase IIa) in HIV patients. small molecule based treatments for pain are characterized by chronic the absence of cognitive Neurotune’s they are safe even for the Therefore, representing a major unmet medical need. and sedative side effects, animal models promises dramatic their unique efficacy in disease improvement in the Furthermore, elderly. treatment of neuropathic pain. MANAGEMENT CEO/CFO Mäder, W. Armin Dr start-ups. 14 years of experience in finance and life-science CSO Vrijbloed, Willem Dr Jan YEAR FOUNDED 2005 EMAIL [email protected] FAX +41 44 200 21 80 TELEPHONE +41 44 200 21 95 ADDRESS 27a Wagistrasse 8952 Schlieren Switzerland CONTACTS Dr Bruno Oesch BD & L Executive Chairman / Head Armin Mäder Dr CEO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Dr Lluís Ribas de Pouplana, CSO Dr Lluís Ribas de Pouplana, 18 years Founder of Omnia Molecular, ICREA Research Professor and PI at the Institute for Research in Biomedicine. Founder, The Scripps Assistant Professor (93-97), Scientist M.I.T. of Edinburgh, PhD Univ. Aminoacyl-tRNA synthetases. experience with Research Institute (97-03). Dr Oscar Rey Puiggròs background in & Omnia Molecular, 8 years experience in Drug Discovery Laboratorios SALVAT MBA (ADE-Ramon Llull), Theoretical Chemistry & Medicinal Chemistry. Molecular Modeling, CFO Torra, Maurici Capital. Venture includes 2 years on 10 years experience on SMEs, MBA (ESADE), BoD Dariusch Mani, Dr. LGP. Madaus, AG, Schering 12 years CEO, 20 years international experience pharmaceuticals & biotech, MBA (IESE), BSci, MBA (IESE), 20 years international pharma leadership positions in USA, Germany and South Africa with Bayer, Solvay and Africa with Bayer, Germany and South 20 years international pharma leadership positions in USA, MBA (IESE), BSci, African subsidiary. 5 years as CEO of South including 8 years global strategy/business development director, Abbott, Omnia Molecular, S.L. Molecular, Omnia www.omniamol.com FINANCIAL SUMMARY $15 million USD ca. to date, $7 million USD invested Capital and Private Investors). Privately held (Venture existing investors and stakeholders. of which 50% is secured through cash flow, required to reach positive 1/10/2010 – $3 Million USD (Animals): A Round- Pre-clinical PoC 1/1/2012 – $5 Million USD Optimization: Planned B Round- Lead 1/1/2014 – $7 Million USD PoC: Planned C Round- Clinical • Currently million from new investors in B Round. seeking $2 • Partnering for industry clinical co-development with pharma partner possible from lead optimization in 2012. • Out-licensing/Exit possible from clinical proof-of-concept. PROFILE COMPANY – Omnia Molecular leverages its proprietary biotech platform novel anti-infectives targeted to design and develop at difficult-to-treat infections. business model is to partner with pharma industry from the proof of concept stage (efficacy in animal – Omnia’s infection model) and out-license drug candidates at (phase IIa). clinical proof of efficacy a multi-resistant Our lead program targets MRSA, – Omnia has platform assets. and new chemical entity of which are fatal. 20% bacteria which causes approximately infections in hospitals per year, 100,000 multi-parametric screening technology in which activity against the The Omnia platform is our patented, – Our platform thereby enables design and optimize new us to pathogen target is measured inside a human cell. chemical entities against target. international in the experience – Omnia is led by professional management team with long-standing, pharmaceutical industry and is advised by highly board. reputed members of its scientific of action forAminoacyl-tRNA Synthetases (aaRS) aaRS Inhibition is a proven mode – Our molecular target is anti-infectives and validated through the commercial success of Mupirocin (Bactroban®). in the marketplace – Our competitive advantage time-lines and increase probabilities is to shorten development of success in the The net effect is to increase productivity and reduce risk and costs. later stages of development. – Probabilities of success in clinic are increased through multi-parametric information on drug effect on human cells in the early stages of development. Klebsiella, – Our platform technology can be applied to a broad spectrum of pathogens including Pseudomonas, Malaria. Mycosis and Tuberculosis, Mycoplasma, Actinobacter, Helicobacter, MANAGEMENT CEO Raphael Gernot Klingmann, YEAR FOUNDED 2005 Incorporation 2008 Begin of lab activity EMAIL [email protected] TELEPHONE +34 934 020 158 (ES) +1 202 657 4327 (US) Raphael Gernot Klingmann +34 664 654 674 Dr Dariusch Mani +41 774 394 290 ADDRESS 15 Baldiri i Reixac, Parc Científic de Barcelona 08028 Barcelona CONTACTS Raphael Gernot Klingmann CEO Dr Dariusch Mani, Board of Directors WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

ORCA Therapeutics BV Therapeutics ORCA www.orca-therapeutics.com FINANCIAL SUMMARY OncologyAglaia Seed Fund BV. Current investor: PROFILE COMPANY (ORCA) is developing a pipeline of innovative anticancer therapies based on the highly Therapeutics B.V. ORCA its proprietary value proposition is based on using technologies ORCA’s promising approach oncolytic of viruses. is a new oncolytic lead product ORCA-010 ORCA’s Agents. in the field of Oncolytic Replication Competent has up to ten thousand fold ORCA-010 higher T1 technology. proprietary Company’s adenovirus based on the oncolytic potency as compared to current state of the art oncolytic adenoviruses in a variety of cancer cell lines and ORCA is currently developing ORCA-010 for its first study in man. MANAGEMENT CEO PhD, Dr Janneke Meulenberg, CSO PhD, Victor van Beusechem, Dr YEAR FOUNDED 2005 EMAIL meulenberg @orca-therapeutics.com FAX +31 204442126 TELEPHONE +31 204441826 ADDRESS De Boelelaan 1118 Amsterdam 1081 HZ The Netherlands Postal address: PO Box 7057 Amsterdam 1007 MB The Netherlands CONTACT PhD Janneke Meulenberg, CEO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u Oxford BioMedica plc BioMedica Oxford www.oxfordbiomedica.co.uk FINANCIAL SUMMARY The placing and open offer which at net cash balance 31 December 2010 was £12.3 million. The Company’s At 31 March 2011 the Companya net had closed on 10 January 2011 raised £18.4 million net of expenses. (unaudited). cash balance of £24.6 million PROFILE COMPANY Oxford is a biopharmaceutical company BioMedica plc (LSE:OXB) developing innovative treatments to improve top-tier profitable Our mission is to build a biopharmaceutical the lives of patients high unmet needs. with company founded and commercialization on the successful development of novel gene-based medicines. which are based on highlyOxford engineered BioMedica has a platform viral of gene delivery technologies, which represent one of the broadest Oxford BioMedica is underpinned by over 80 patent families, systems. patent estates in the field. The lead product regulatory and manufacturing know-how. Oxford BioMedica also has in-house clinical, which is in Phase II development for the a therapeutic vaccine for multiple solid cancers, TroVax®, candidate is treatment of hormone refractory prostate cancer. a novel gene-based including ProSavin®, The Company development, has three other products in clinical AMD, a novel gene-based medicine for wet in Phase I/II trial; RetinoStat®, disease, treatment for Parkinson’s a novel gene-based medicine for the treatment juvenile macular of the inherited in Phase I/II and StarGen®, I/II. Phase disease, Stargardt’s degeneration disease, Technology VirXsys. MolMed and Sigma-Aldrich, Wyeth, Oxford BioMedica has collaborationsSanofi, with GlaxoSmithKline and Pfizer. Merck & Co, licensees include Biogen Idec, MANAGEMENT Chief Executive Officer John Dawson, Chief Scientific Officer Stuart Naylor, Chief Financial Officer Wood, Andrew Vice President Senior Nolan, Peter J. Director Alex Lewis, YEAR FOUNDED 1995 EMAIL [email protected] FAX +44 (0) 1865 783001 TELEPHONE +44 (0) 1865 783000 ADDRESS Oxford BioMedica plc Medawar Centre Avenue Robert Robinson Oxford Science Park Oxford OX4 4GA United Kingdom CONTACT Alex Lewis Dr & Activities Director Corporate Strategy WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u Pantec Biosolutions AG AG Biosolutions Pantec www.pantec-biosolutions.com PROFILE COMPANY (Precise Laser The Company´s P.L.E.A.S.E.® in microporationPantec Biosolutions specialises technology. customizable a settings and precise treatment profile, Epidermal System) platform features a safe (Class I), offers new treatment and traditional dermatology options in aesthetic as well as P.L.E.A.S.E. compact design. microporation and transdermal delivery of biopharmaceuticals. combination treatments –i.e. MANAGEMENT Chief Executive Officer Dr Christof Böhler, Chief Business Officer PhD, Sven Rohmann MD, Officer Technology Chief Thomas Bragagna, as permanent Consultant Clinical Director, Dr Norbert Clemens, YEAR FOUNDED 2005 EMAIL [email protected] Christof.boehler @pantec-biosolutions.com FAX +423 377 78 99 TELEPHONE +423 377 78 00 ADDRESS AG Pantec Biosolutions Industriering 21 9491 Ruggell Liechtenstein CONTACTS Dr Christof Böhler Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Pevion Biotech AG Biotech Pevion www.pevion.com FINANCIAL SUMMARY the August 2007, In as start-up capital. provided CHF 20 million Biotech and Bachem, Berna The two founders, BB Aktiengesellschaft, investors BZ Bank A financing round with new Company 15 million series closed a CHF After the acquisition of AG. Bachem the existing investor as well as, and Core Capital Partners, Ventures Biotech In September participation in November 2007. was bought out Crucell’s Berna Biotech by NV in 2006, Crucell investors. additional CHF 10 million in financing from its current Pevion secured 2010, PROFILE COMPANY AG is a fully independent Swiss vaccine company that develops innovative vaccines for unmet Pevion Biotech Its proprietary clinical medical needs based on its clinically and commercially validated virosome technology. A clinical stage malaria vaccine candidate has been pipeline includes a first-in-class candidiasis vaccine. technology has been licensed for vaccine currently use as an HIV and the Company’s successfully out-licensed, including a state-of-the-art and Pevion has in-house development capability and expertise, in human trials. Pevion was established by its founding Located near Bern, industrially scalable GMP manufacturing process. date, To a Johnson & Johnson subsidiary). BANB) and Berna Biotech (now Crucell, AG (SWX: Bachem fathers, CCP and BB BZ Bank, Pevion has raised a total of CHF 45 million to date from its founders investors, and Ventures. Biotech MANAGEMENT Chief Executive Officer Evert Kueppers, Head of Finance Urs Berchtold, Head of Research PhD, DVM, Christian Moser, Head of Process Development & Manufacturing PhD, Amacker, Mario Head of Project Management & Clinical Development PhD, Christian Spyr, YEAR FOUNDED 2002 EMAIL [email protected] FAX +41 31 550 4445 TELEPHONE +41 31 550 4444 ADDRESS 32 Worblentalstrasse CH – 3063 Ittigen/Bern Switzerland CONTACT Evert Kueppers Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Phylogica Ltd Phylogica www.phylogica.com FINANCIAL SUMMARY ASX IPO on 2005: A$25M Equity raised: PROFILE COMPANY drug which provides peptide UK, and Oxford, Australia Phylogica is a biotechnology company based in Perth, discovery services to the Pharmaceutical industry. Phylogica and patented has discovered a unique proprietary class of targeted peptide therapeutics (Phylomer® and commercial advantages over manufacturing, therapeutic, These peptides exhibit competitive peptides). therapeutic monoclonal antibodies and most current other more traditional targeted biologics proteins, such as peptides. which constitute the most structurally diverse set of Libraries of billions of Phylomers have been constructed, Medimmune/ Roche, include partners Current hits. of quantity and quality higher a in resulting available, peptides AstraZeneca and Pfizer. YEAR FOUNDED 2003 EMAIL [email protected] FAX +61 8 9382 1766 TELEPHONE +61 8 9382 8888 ADDRESS 100 Roberts Road Perth Australia 6008 Western Australia CONTACTS Watt Dr Paul Chief Executive Officer [SPEAKER] Woolf Nick VP Chief Financial Officer & Corporate Development WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Phytopharm plc Phytopharm www.phytopharm.com FINANCIAL SUMMARY the majority of our operations we continue to outsource to specialist In line with our virtual operational structure, This lean external organisationsenabling us to operate and minimal infrastructure. with a low headcount operational the nature substantial cost and technical benefits as structure confers of our activities and range Efficiency and cost control change as our programmes progress through the various stages development. of continue to be a key focus. to progress in December 2009 to provide the resources Phytopharm raised £24 million of its the development Cash at million. 31 March 2011 totalled £20 pharmaceutical programmes. PROFILE COMPANY and listed on the UK Phytopharm is a development stage company biopharmaceutical based in Huntingdon, London Stock Exchange (LSE:PYM). small lead products are first in class, Phytopharm’s main focus is in neurodegenerative disease. The company’s molecule neurotrophic factor inducers which have the potential to be important new treatments by protecting neuronal degeneration modifying characteristics. and providing true disease ALS Phytopharm is approaching important data glaucoma and disease, With lead programmes in Parkinson’s milestones over the coming 2 years. and The company will seek licensing partners for its products when key development milestones are achieved, also seeks to add its pipeline with via synergistic alliances. YEAR FOUNDED 1996 EMAIL [email protected] FAX +44 1480 417090 TELEPHONE +44 1480 437697 ADDRESS Phytopharm plc Lakeview House 2 Lakeview Court Ermine Business Park Huntingdon PE29 6UA UK CONTACTS Sharpington Tim CEO Patrick Howson Head of Preclinical Research WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

PIQUR Therapeutics AG Therapeutics PIQUR www.piqur.com PROFILE COMPANY Therapeutics is an early stage venture PIQUR Founded in 2011 as a spin-off company of University of Basel, 3rd and 4th generation cancer therapeutics targeting the biopharmaceutical company developing best-in-class, PIQUR is confident that it is the leader in the With its 3rd and 4th generation agents, PI3K-Akt-mTOR pathway. the PI3K cancer pathway. development of drugs tackling pathwayThe PI3K-Akt-mTOR cancer important cancer pathways is considered one of the three most and is non-small cell lung, breast, thyroid, gliomas, associated with many tumor types including pancreatic cancers, Nature Reviews Drug Discovery). 2009, stromal and bile duct cancers (Liu et al., gastro-intestinal gastric, Some 2nd generation agents have the clinic and have reached demonstrated that PI3K/mTOR inhibition is these products have fallen short of efficacy and tolerance However, feasible – providing clinical proof of concept. requirements and new generations of more effective and better tolerated agents are needed. backed by and its global network of PI3K development specialists knowhow and leadership position, PIQUR’s have for been responsible the creation of its collaborators within the Oncology Basel University Hospital, Unit of agents which have dual PI3K- overcome the complex novel 3rd and 4th generation cancer-fighting PIQUR’s tailored providing optimal therapies, faced bymTOR inhibition and physico-chemical problems other companies, to the unique needs of each cancer. MANAGEMENT Vladimir Cmiljanovic Dr Wymann Prof Matthias Prof Bernd Giese Andreas Emmenegger Ralf Rosenow YEAR FOUNDED 2011 EMAIL [email protected] FAX +41 61 267 3566 TELEPHONE +41 61 695 3140 ADDRESS AG Therapeutics PIQUR Winde-Strasse 120 Hohe CH-4059 Basel Switzerland CONTACTS Ph.D. Vladimir Cmiljanovic, EMBA Andreas.Emmenegger, WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

ProFibrix BV ProFibrix www.profibrix.com PROFILE COMPANY ProFibrix leveragesexpertise in fibrinogen technology its and market innovative to develop products for the plays Human fibrinogen a pivotal role in blood clotting and hemostasis and regenerative medicine markets. clinical and scientific experience in the field is led by ProFibrix a team with extensive commercial, tissue healing. is being studied to help stop biologic, lead the proposed name of the company’s Fibrocaps™, of hemostasis. A dry and thrombin, powder based on a mixture of fibrinogen bleeding during surgery and after trauma injury. Fibrocaps preparation is a ready-to-use designed to be stable at room temperature and applied in different Fibrocaps is currently wrappingand is up Phase 2 clinical studies sprays including and bandages. formats, in 2012. scheduled to enter into a final pivotal Phase 3 study MANAGEMENT CEO Jan Öhrström, CSO Jaap Koopman, CBO Arnoud Dijkstra, VP Finance Martijn Meijer, CDO Eliane Schutte, CMO Paul Frohna, VP Preclinical Linda Zuckerman, YEAR FOUNDED 2005 EMAIL [email protected] [email protected] [email protected] FAX +31 715 181340 TELEPHONE +31 888 669665 ADDRESS Zernikedreef 9 Leiden 2333 CK, The Netherlands CONTACTS Jan Öhrström CEO Jaap Koopman CSO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

PSites Pharma GmbH Pharma PSites www.psites.de FINANCIAL SUMMARY GO-Bio grant and PSites Pharma GmbH is looking to get its current PSites has been awarded by a new € 2,9 M. € 1.5 M are still open. A round of € 7 M completed where PROFILE COMPANY the next generation developing of kinase a spin-offPSites Pharma GmbH is from the University Frankfurt, inhibitors. PSites has AGC- protein kinases in 2000, binding site for Based on the discovery of a non-ATP-competitive libraries and other tools for the development of developed a complete platform systems, of special screening very specific kinase inhibitors. First lead structures for lung cancer and diabetes had shown very results. promising in vivo to be agreed kinase PSites is looking for research collaborations to develop clinical candidates for selected, targets. MANAGEMENT CEO Witte, Dr Rolf CSO Dr Ricardo Biondi, YEAR FOUNDED 2011 EMAIL [email protected] FAX +49 211 617 851 51 TELEPHONE +49 211 851 11 ADDRESS 29 Jugenheimer Str. 60528 Frankfurt Germany CONTACTS Witte Dr Rolf CEO Dr Ricardo Biondi CSO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Riboxx GmbH Riboxx www.riboxx.com FINANCIAL SUMMARY funded and generatesVC sales and distribution in Germany revenues through direct and Europe. The company is The company has successfully launched its products and services in 2010 generating stable income with more The company rapidly share and is currently increases its market expanding its technology than 80 customers. into therapeutic and diagnostic areas. PROFILE COMPANY technologyRiboxx has developed a new to generate siRNA/miRNA candidates with strongly enhanced silencing activity and attractive in vivo behaviour to facilitate therapeutic and diagnostic applications. Riboxx has developed its innovative tools for gene silencing in vivo and secured these with trademarks such as the CONTRAmir® and CONmir® as well as an innovative process of RNA in synthesis the IVORI® in vivo siRNA, large scale termed ENOVA®. RNA/siRNA/ VIVO siRNA, A new class of IN The IP portfolio of Riboxx relates mainly three fields of inventions: to biocatalysis of chemically modified RNA/siRNA/miRNA. miRNA synthesis and analytics, as well as many The IP portfolio of Riboxx includes ten international patents families with a granted patent in EU, “CONmir®”. and “CONTRAmir®” “ENOVA®”, “RNA interference in a box®”, “Riboxx®”, brands among them Riboxx is currently searching for to further develop the diagnostic partnerships and therapeutic potential. MANAGEMENT CEO and Founder MSc, MD/PhD, MBA, Dr Jacques Rohayem, Production and Quality Executive and Finance, The company has so far 18 employees and four departments: and Marketing and Sales. Research and Development, Management, YEAR FOUNDED 2009 EMAIL [email protected] FAX +49 351 833 60139 TELEPHONE +49 351 833 6010 ADDRESS Riboxx GmbH Pharmapark Radebeul, 191, Meissner Str. 01445 Radebeul Germany CONTACT Rohayem (CEO) Dr J. Chief Executive Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u • B-Round 5m€ end of 2011 • C-Round 10m€ 2013. 15 years industry experience in R&D, IP, licensing and VC deals at Novartis (Switzerland) and Zeltia Group (Spain) licensing and IP, 15 years industry experience in R&D, Rubén Henríquez, Ph.D., MBA, CBO MBA, Ph.D., Rubén Henríquez, 25 years international experience, CEO at large multinational and start-up pharma companies, founder, PE fund investor founder, CEO at large multinational and start-up pharma companies, 25 years international experience, CMO M.D., Pieter Joubert, pharma industry advisor, Switzerland, Roche, former Global Head Clinical Pharmacology, 30 years industry experience, Professor Pharmacology UK in SA and CSO Ph.D., Joan Perelló, founder/president Biotech cluster 10 years R&D experience, Founder of Sanifit and co-inventor in key IP. COO Ph.D., Bernat Isern, 10 years R&D management Founder of Sanifit and co-inventor of key IP. SANIFIT Laboratoris, S.L. S.L. Laboratoris, SANIFIT www.sanifit.com FINANCIAL SUMMARY funds, Good access to public funding so far 6m€. Total founders and private investors. VC, Privately held by (Phase I + II) and reach positive cash flow conclude clinical trials To milestones. strong track record meeting of 10-12m€ from new Seeking commitment provide up to 50%. Existing stakeholders 20m€ required. investors. Positive overall cash flow from partnering is products generatesOut-licensing of the dental revenues from 2012. expected in 2015. PROFILE COMPANY with a pipeline prescription medicines (Rx) focused on Sanifit offers a new approach for calcification disorders, The international management team has proven track record and long industry and selected OTC products. experience. out-license/partner for to clinical prove of concept and The business model is to develop the products up final development and commercialization. It targets renal dialysis patients reducing I clinical trials. The lead Rx product (SNF472) is entering Phase includes drugs The pre-clinical pipeline for related to high morbidity and mortality. cardiovascular calcification, renal areas. severe chronic diseases in the cardiovascular and where Sanifit explores The IP protected technologydevices, in medical nutrition and medical covers also the use applications jointly with partners. efficacy were successfullyOTC dental care products with outstanding clinical developed and are in the commercial partnering/launch phase. realization through spin-offs of OTC and major licensing deals for Rx with attractive in exit potential Value 2014/15. MANAGEMENT CEO MBA, Ph.D., Dariusch Mani, YEAR FOUNDED 2007 (activities commenced) EMAIL [email protected] [email protected] FAX + 34 871 962 545 TELEPHONE +34 971 439 925 Switzerland Dariusch Mani +41 77 4394 290 Spain Joan Perello +34 647 485 999 ADDRESS SANIFIT Laboratoris Building Disset Parc Bit, 07121 Palma de Mallorca SPAIN CONTACTS Switzerland Dariusch Mani CEO Spain Joan Perello CSO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u 3,469 43,682 20,609 - 9,638 - 8,711 - 11,256 - 29,694

ANY PROFILE ting result: ting result: ting expenses: otal revenue: otal revenue: Helmut Kessmann, Chief Business Officer [email protected] Phone +41 906 89 56 [email protected] Phone +41 906 89 62 Chief Financial Officer Barbara Heller, [email protected] Phone +41 906 89 54 Chief Scientific Officer Thomas Meier, [email protected] Phone +41 906 89 64 Opera Santhera is a Swiss specialty pharmaceutical company focused development and commercialization on the of innovative therapies for niche indications severe orphan and with a focus on neuromuscular and areas of high unmet medical need which includes many orphan indications with no neurodegenerative diseases, current therapy. to treat Catena®, first product, The indications. pipeline consists of three compounds in seven Santhera’s MAA in the EMA is currently reviewing the Company’s In Europe, Ataxia is marketed in Canada. Friedreich’s The drug is also being investigatedin Duchenne in a Phase III study Hereditary Optic Neuropathy. Leber’s syndrome (in collaborationMuscular Dystrophy; in a Phase II study in MELAS with Columbia University of New City); and in Phase I/II in Primary Progressive Multiple Sclerosis (in collaboration with the US National York Commercial rights in Europe forMuscular Dystrophy Duchenne Institute of Neurological Disorders and Stroke). Pharmaceutical. Takeda are licensed to second compound fipamezole is currentlyprepared for Phase III development as potentially first Santhera’s Development and commercialization rights Disease. treatment of levodopa-induced Dyskinesia in Parkinson’s America and Japan are partnered with Ipsen. outside North third compound omigapil Novartis for was in-licensed from development in Congenital Muscular Santhera’s Preparation for Phase II/III development is ongoing. Dystrophy. www.santhera.com. please visit the Company’s For further information, MANAGEMENT Chief Executive Officer Klaus Schollmeier, Cash burn: T Net sales: Net loss: Santhera Pharmaceuticals Pharmaceuticals Santhera www.santhera.com FINANCIAL SUMMARY CHF thousands) 2010, December 31, Fiscal year 2010 (ended Cash reserves: Opera COMP YEAR FOUNDED 2004 EMAIL [email protected] [email protected] FAX +41 61 906 89 51 TELEPHONE +41 61 906 89 50 Thomas Staffelbach +41 906 89 47 ADDRESS Hammerstrasse 49 4410 Liestal Switzerland CONTACT Thomas Staffelbach RelationsVP Head Public & Investor WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u Scil Proteins GmbH GmbH Scil Proteins www.scilproteins.com FINANCIAL SUMMARY €24 mm Financing Round 2011: PROFILE COMPANY Affilin® molecules and working companyScil Proteins is a biopharmaceutical discovering and developing Affilin® with industry therapeutics in the development and manufacture of protein partners diagnostics. and molecules are therapeutics and diagnostics based on a scaffoldderived from the human protein Ubiquitin to discovery Scil Proteins’ form highly stable immunogenicity. molecules with strong binding specificity and low Affilin® platform is a fully patent technology protected screening for the identification of target-specific Affilin® therapeutics Scil Proteins has generated a pipeline of molecules using advanced selection systems. It also offers the technology to the industry for collaborativetargeting cancer and other therapeutic areas. production and development, With a longstanding expertise in protein discovery and development partnerships. Scil Proteins also offers to biotech and pharma and process development GMP contract bio manufacturing Germany. Scil Proteins is a well-established private company located in Halle, companies. learn more about www.scilproteins.com Scil Proteins please visit To MANAGEMENT CEO Dr Ulrike Fiedler, CBO Dr Ulrich Haupts, CBO Afflerbach, Dr Henning CFO Frank Ubags, YEAR FOUNDED 2000 EMAIL [email protected] FAX +49 345 27996 332 TELEPHONE +49 345 27996 330 ADDRESS Scil Proteins GmbH 1 Heinrich-Damerow-Strasse 06120 Halle (Saale)Germany CONTACT Frank Ubags Chief Financal Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Siena Biotech S.p.A Biotech Siena www.sienabiotech.com FINANCIAL SUMMARY the Monte dei Paschi di Siena Siena Biotech is a privately held company founded by shareholder, its major Foundation. Siena FoundationThe Monte dei Paschi di is a non-profit organization operating totally within the sphere of primarily derived from its private law aims of social utility through the management which pursues of its assets, Paschi di Siena Bank. major stake in Monte dei Siena Biotech is an operational arm of Monte dei Paschi di Siena Foundation to achieve its objectives. PROFILE COMPANY Siena Biotech is a drug discovery and development company with a consolidated portfolio of disease modifying small molecule therapeutics for oncology neurodegenerative and diseases aiming to prolong and improve the quality of patients’ lives Siena Biotech has secured top level management executives leading an established team of talented Combining our drug discoverydevelopment expertise with an integrated and platform of international scientists. we have diversified pipeline of developed a cutting edge technologies research centre, housed in a purpose-built including rare in-licensed and proprietary products for oncology and neurodegenerative indications, partnered, diseases. Alzheimer Disease in partnership with leading pharmaceutical Siena Biotech has delivered candidates for In July 2011 Siena Biotech received a further undisclosed payment from Roche based on the companies. Alzheimer’s achievement of a key at milestone in a project aimed developing disease-modifying therapies for disease. a devastating hereditary Disease, Our fight to develop a disease modifying therapy against Huntington’s a Sirtuin 1 inhibitor has lead us to clinical development of SEN196, neurodegenerative disease with no cure, product is currentlyThe in Phase II trials in patients with HD and has in licensed from Elixir Pharmaceuticals. Ageing in and the EMEA and the Department of Health achieved Orphan Drug status for FDA, HD from the In 2011 Siena Biotech signed an alliance with CHDI aimed at the validation of novel therapeutic targets Australia. for HD. Wnt the Hedgehog and Siena Biotech has developed significant experience in both In the field of oncology, Therapeutics a collaboration Siena Biotech has signed agreement with the Experimental signalling pathways. Agency for two research units under Singapore’s Centre (ETC) and Singapore Immunology Network (SIgN), expertise and equity of The collaboration leverages Siena Biotech’s and Research (A*STAR). Technology Science, Wnt pathway modulators with ETC and SigN capacity antibodies respectively, to develop new drugs and targeted aiming to help millions of cancer and bone loss patients across the world. MANAGEMENT CEO and General Manager Giovanni Gaviraghi, Deputy Director Alberto Faleri, Alliances Director of Portfolio Operations and Thomas, Russell YEAR FOUNDED 2000 EMAIL [email protected] FAX +39 0577 381 323 TELEPHONE +39 0577 381 409 ADDRESS Siena Biotech S.p.A. Strada del Petriccio e Belriguardo, 35 53100 Siena ITALY CONTACTS Thomas Dr Russell Director of Project Operations Alliances and Dr Giovanni Gaviraghi CEO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

sigma-tau research Switzerland SA Switzerland research sigma-tau www.sigmatau.com PROFILE COMPANY is an R&D Company Group specialized in the development of the sigma-tau S.A. sigma-tau Research Switzerland of novel and innovative drugs. where is mainlysigma-tau Research Switzerland focused on highly therapeutic specialized areas as oncology, either as small molecules (e.g. anticancer agentsSTRCH is developing new acting on innovative targets, anti-Met). antibodies (e.g. hearanase inhibitors) or monoclonal R&D (chemical and analyticalIt also provides technical and development) and clinical development competences services. MANAGEMENT President Marco Brughera, CEO & GM Alessandro Noseda, YEAR FOUNDED 2004 EMAIL alessandro.noseda @st-research.ch francesca.mancuso @st-research.ch FAX +41 91 640 4059 TELEPHONE +41 91 640 4051 ADDRESS Stazione- PO BOX 1823 Mendrisio Via Motta 2a 6850 Mendrisio (CH) CONTACTS Alessandro Noseda CEO & GM Francesca Mancuso Assistant Administrative WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

(DME, AMD) (DME, (Prevention of Delayed Graft Function, Acute Kidney Injury) partner: Quark/Novartis Quark/Novartis Acute Kidney Injury) partner: (Prevention of Delayed Graft Function, PF-4523655(AtuRNAi),  Pfizer/Quark Pharma (Phase II); partner: QPI-1002 (AtuRNAi), (Phase II ); SILENCE has a strong IP portfolio providing proprietary position and freedom to operate. The Company has SILENCE has a strong IP portfolio providing proprietary position and freedom to operate. performed different more than 100 pre-clinical studies in (mouse/rat/non-human animal models primate). April 2011 there are 5 clinical programs (four in phase II and Out of 13 clinical siRNA programs of worldwide as partners Pfizer/ AtuRNAi molecules of which four are developed by SILENCE’s one in Phase I) with SILENCE’s leadership in the field of siRNA therapeutics. Quark and Quark / Novartis which confirms SILENCE’s Summary Products: - - Phase I) Lung & Other Cancers, Atu027 (AtuRNAi) (GI, - Atu111 (AtuRNAi) (Acute Lung Injury); Internal (Preclinical) - Internal (Preclinical) Tumors); Atu134 (AtuRNAi) (Solid - Internal (Preclinical) Tumors) Atu195 (AtuRNAi) (Solid - MANAGEMENT Senior Management AG Therapeutics Therapeutics plc and Chief Executive Officer of Silence COO of Silence Thomas Christély, Finance Director & Company Secretary Max Herrmann, CSO Dr Klaus Giese, Vice President Research Dr Jörg Kaufmann, Board of Directors Chairman Jerry Randall, Max Herrmann Dr David Mack Dr David U’Prichard Annette Clancy SILENCE believes thatproprietarybelieves and SILENCE broad this therapeuticsRNAi deliveryand and technologies support can base industrypharmaceutical the with therapeuticof opportunities. partnerships multiple range diverse advance a across proprietary siRNA technology (AtuRNAi) and proprietaryThe Company has developed a novel, systemic delivery These sophisticated and flexible delivery options allow Silence to DACC and DBTC). systems for siRNA (AtuPLEX, offer potential partners a choice of technologies to deliver RNAi molecules to a broad range of targeted diseased tissues. Silence Therapeutics plc Therapeutics Silence www.silence-therapeutics.com COMPANY PROFILE COMPANY SLN) is a leading global biotechnology company dedicated to the discovery, Therapeutics plc (AIM: Silence (RNAi) therapeutics systemic RNA interference for the treatment of serious development and delivery of targeted, diseases. comprised of SILENCE offersthe most comprehensive RNAi therapeutic one of platform available today, proprietary RNA (siRNA) sequences and innovative potent short interfering siRNA structural delivery technologies, proprietary siRNA technology (AtuRNAi) and proprietaryThe Company has developed a novel, systemic features. DACC and DBTC). delivery for systems siRNA (AtuPLEX, consists of both partnered which includes five product candidates in clinical development, SILENCE pipeline, Atu027 is currently in a Phase I clinical study for the treatment lead compound Silence’s and internal programs. the compound has been shown to be and to date, Atu027, 24 patients had been treated with of solid tumours. Annual American Society of Clinical Oncology Interim data have been presented at the safe and well tolerated. Meeting in June 2011. milestone payments) partnerships with Quark/Pfizer ($95m and Quark/Novartis ($80m In addition to Silence’s AstraZeneca ($15m upfront/$400m milestone Silence has active collaborations with milestone payments), payments) and Dainippon Sumitomo ($2m upfront). TECHNOLOGY YEAR FOUNDED October 1994 EMAIL t.christely @silence-therapeutics.com m.herrmann @silence-therapeutics.com k.giese @silence-therapeutics.com FAX +44 20 7491 6521 (London) +49 30 9489 2801 (Berlin) TELEPHONE +44 20 7491 6520 (London) +49 30 9489 2800 (Berlin) ADDRESS plc Therapeutics Silence Britain Great of Institution Royal The Albemarle Street 21 W1S 4BS London Great Britain AG Therapeutics Silence Robert – Roessle – Strasse 10 13125 Berlin Germany CONTACTS Thomas Christély Mr Chief Operating Officer, Therapeutics plc and Silence Chief Executive Officer, AG Therapeutics Silence Mr Max Herrmann Finance Director & Company Secretary Dr Klaus Giese Chief Scientific Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u A powder form is being

3 mm+. 3 mm+.

liquid formare being developed for an IV drip the ethical

Private investment by founders

COMPANY PROFILE COMPANY side has minimal has been tryingFor years the pain market to identify a form aspirin that of is non addicting, delivered both in an injectable and can be and IV form patients..After to 5 years of research such effects, patentedquantities. and manufactured in small a product has been developed, market. clinical trials for market as it is ready to enter Soluprine is ready to be introduced to the investment at least 9 which is being The company million dollars for is seeking 3-5 the complete clinical trial program, indications. managed by Covance. for additional information.. Please contact StanYakatan Soluprin Pharmaceuticals, Inc. Pharmaceuticals, Soluprin FINANCIAL SUMMARY Capital invested: developed for market and a sublingual, the OTC

YEAR FOUNDED 2005 Dr Phil Felice ADDRESS Beach, 245 33rd Street Hermosa Califiornia 90254 USA +786 229 9795 +631 379 4262 CONTACTS Yakatan Stan WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Stabilitech www.stabilitech.com FINANCIAL SUMMARY The company has raised a total of £7.5 Stabilitech is funded by business angels and non-dilutive funding. US part of the Stabilitech has won a contract with DTRA, three funding rounds (including seed). in million so far, with a value of up to $4 million over 3 years. Department of Defense, PROFILE COMPANY biopharmaceuticals and Stabilitech a novel proprietary has developed technology which stabilizes vaccines, It will enable term the long The inspiration for the technology came from nature. other biological products. and has been applied stable storage of vaccines and other biological products over a range of temperatures, approachof selected involves the addition Stabilitech’s to a variety of vaccine and biopharmaceutical classes. The excipients have all been followed by freeze drying. excipients at optimised concentrations and ratios, and are inexpensive and readily available. previously used in clinical settings, biotech and animal health companies. business model is to license the technology to pharma, Stabilitech’s in the London Bioscience Innovation Centre. Stabilitech is a private company based in London, MANAGEMENT Chief Executive Officer Dr Barbara Domayne-Hayman, Chief Scientific Officer Dr Jeff Drew, Development Director Ward, Dr Stephen Commercial Director Ms Donna Hackett, YEAR FOUNDED 2004 EMAIL [email protected] TELEPHONE +44 20 7691 3567 +44 7771 635450 ADDRESS Stabilitech Ltd London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH UK CONTACTS Dr Barbara Domayne-Hayman CEO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Syndax Pharmaceuticals Inc. Pharmaceuticals Syndax www.syndax.com FINANCIAL SUMMARY A:$49M Series • MLC Ventures • Forward Ventures Avalon • Ventures Associates • MPM Capital • Pappas • Domain Investors: Seeking Series B 2011. PROFILE COMPANY Syndax is a late-stage epigenetics oncology company focused on mechanisms of drug resistance in solid tumors placebo controlled Phase 2 trial recently completed a randomized, We entinostat. with worldwide rights to Aromasin® in patients with advanced/metastatic and are moving this breast cancer evaluating entinostat with randomized phase 2 study showed a four- results from a placebo controlled, Also, program into phase 3 testing. month survival advantage when entinostat was added to erlotinib in patients lung cancers expressing high with ‘double’ Phase 2 In collaboration with investigators at the NCI, Johns Hopkins University and levels of E-cadherin. Vidaza® entinostatepigenetic clinical studies are being conducted with methyltransferase inhibitor, and the DNA based on the objective clinical responses previously reported in a lung cancer trial. in solid tumors, Salk Institute. Ph.D., and Ron Evans, Associates, Domain M.D., Weber, Syndax was founded in 2005 by Eckard please visit www.syndax.com For more information, MANAGEMENT Senior Management Chief Executive Officer MD, Joanna Horobin, Ph.D., Chief Business Officer Bob Goodenow, VP Product Development Miranda Rees, Chief Medical Officer FFPM, FRCP, ChB, MB, William McCulloch, Affairs Regulatory VP, Caryn Peterson, Board of Directors/Affiliation Associates Domain Chairman, Dennis Podlesak, Associates Ph.D., Domain Kim Kamdar, MPM Capital MD, Peter, Steven St. Ventures Pappas MD, Rosina Maar Pavia, YEAR FOUNDED 2005 EMAIL [email protected] [email protected] [email protected] FAX +1 781 419 1420 TELEPHONE +1 781 419 1400 ADDRESS Inc. Syndax Pharmaceuticals, Suite 650 Pond Road, Totten 460 02451 MA Waltham USA CONTACTS Dr Joanna Horobin Chief Executive Officer Dr Bob Goodenow Chief Business Officer Mr John Pallies Finance Director, WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Syntaxin Ltd Syntaxin www.syntaxin.com FINANCIAL SUMMARY and a £16m Series in November 2005, Abingworth A financing with The Company a £6m Series completed Johnson & Johnson Abingworth, with B financing led One and Life Science Partners in October 2007, by SR a Series C round raised £18m 2010, In October Development Corporation and Quest for Growth co-investing. Johnson & Johnson Development LSP, One, SR Abingworth, and included participation from existing investors The funds will and Seventure. Ventures Lundbeckfond and new investors Ipsen, for Quest Growth, Corporation, (TSI) technology Secretion Inhibitor platform, Targeted enable the potential of its innovative Syntaxin to maximise Acromegaly programmeof Concept studies. into Proof as well as take its lead internal PROFILE COMPANY Syntaxin was founded in late from the UK of intellectual property and scientists 2005 through spin-out toxin and benefits from 15 years of research in the field of bacterial Porton Down, Agency, Health Protection and use of novel manufacture The company patents holds dominant and know how in the design, engineering. These drugs inhibit secretion Secretion Inhibitors (TSI) based on engineered botulinum toxins. Targeted cell so are convenient treatmentfor of chronic from a specific target cell after a single dose, for a prolonged period disease. metabolic Cell secretion plays endocrine, of numerous diseases including an important role in the development proprietory technology enables the generation of Syntaxin’s pain. as well as chronic certain cancers, disorders, novel therapeutic proteins with broad applicability across these major disease areas. MANAGEMENT Chief Executive Officer Dr Melanie Lee, Chief Business Officer Dr Nigel Clark, Chief Financial Officer Dr Phil Boyd, Chief Development Officer & Research Director Dr Jon Court, Chief Medical Officer Dr Richard Jones, Officer Technology Founder & Chief Dr Keith Foster, YEAR FOUNDED 2005 EMAIL [email protected] FAX +44 (0) 1235 552200 TELEPHONE +44 (0) 1235 552100 ADDRESS Syntaxin Ltd The Quadrant, Units 4-10 Barton Lane Oxon, Abingdon, OX14 3YS UK CONTACTS Dr Melanie Lee Chief Executive Officer Dr Nigel Clark Chief Business Officer Dr Phil Boyd Chief Finance Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u

Previously CEO at Celltech Pharmaceuticals Ltd, ACE Biosciences A/S and Action Pharma A/S, and has held executive A/S, Action Pharma A/S and ACE Biosciences Previously CEO at Celltech Pharmaceuticals Ltd, A/S. management positions at Novo Nordisk CDO Mike Darsley, has led development ACE527 program started, Acambis where VP research at Previously at IGEN Inc. NIH Fogarty fellow. throughout programme. TD Vaccines A/S TD Vaccines www.tdvaccines.com PIPELINE – ph II Vaccine ETEC ACE527: – pre-clinical Vaccine ETEC/Campylobacter ACE920: – pre-clinical Vaccine Campylobacter Poultry ACE393: PROFILE COMPANY The company is focused A/S is a Danish biotechnology company established 2009. in November Vaccines TD of tourist and millions Every year, to protect againston the development of vaccines travellers’ (TD). diarrhoea TD. half of these succumb to and around America, Africa and Latin Asia, business travellers visit destinations in ETEC vaccine to protect against an oral ETEC (Enterotoxigenic E Coli). ACE527, lead programme is Vaccines’ TD haveACE527 has completed Phase I trials in the US and Proof of Concept Phase II challenge trial completed the TD in the market. There currently to prevent is no vaccine in early 2011 with very encouraging results. designed to protect ACE920, is an oral combination vaccine, at a preclinical stage, Earlier in development, against ETEC and Campylobacter infections. Vækstfonden and Dansk is backed by the Danish venture capital investors Sunstone Capital, Vaccines TD Erhvervsinvestering. COLLABORATION ACE527, of has been supporting the development an international nonprofit global health organization, PATH, Vaccines on the earlier TD and collaborated with specifically populations, for use with children in resource-poor trials. MANAGEMENT CEO Ingelise Saunders, YEAR FOUNDED 2009 EMAIL [email protected] TELEPHONE +45 20203687 ADDRESS Rauf Aspvej 12, DK-9520 Skørping Denmark CONTACT Ingelise Saunders CEO WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u MANAGEMENT Chief Executive Officer Eduardo Bravo, Chief Finance Officer Claudia D’Augusta, Chief Business Officer Gil Beyen, Chief Operating Officer Wilfried Daelemans, TiGenix NV (NYSE Euronext Brussels: TIG) is a public biomedical company that focuses on ‘Living Medicines’. ‘Living Medicines’. TIG) is a public biomedical company that focuses on NV (NYSE Euronext Brussels: TiGenix The company the power of cell therapy is exploiting and regenerative medicine to develop durable treatments The company in cell therapy is the leader in Europe with facilities in Leuven for damaged tissues. and diseased (the Netherlands). Cambridge (the United Kingdom) and Sittard-Geleen Madrid (Spain), (Belgium), has two products approved now for marketing and sales in Europe: TiGenix is the first cell-based product lead product for cartilage regeneration in the knee, the company’s ChondroCelect®, to central over clinical development that successfully track from research, completed the entire development chondrocytes ChondroCelect consists of characterized cultured European registration as a medicinal product. a surgical own cartilagefor and is used autologous chondrocyte implantation (ACI), derived from the patient’s Authorization as the first ChondroCelect received European Marketing procedure to treat cartilage defects. Therapy Medicinal Product and is reimbursed in Belgium. Advanced collagen based implant for the treatment osteochondral (cartilage of small ChondroMimetic™ is an off-the-shelf, approvalCE-mark received ChondroMimetic for treatmentand the chondral small of underlyingand defects. bone) It will be marketed as a procedure pack with the collagen in an accurate, implant preloaded subchondral lesions. easy to use delivery device. its proprietary exploits TiGenix adult stem cell platform to develop a new generation of off-the-shelf cell-based products for the treatment inflammatory of autoimmune and diseases which to date represent an area of high medical unmet need. cell platform stem is based on an extensive preclinical and regulatoryTiGenix’ package that has been fully The current pipeline includes Cx601 (orphan drug,) which received validated according to EMA requirements. Cx611, disease patients in 2010, positive Phase IIa data for the treatment complex perianal fistula in Crohn’s of which entered Phase I/II development in rheumatoid arthritis and several other programs in earlier development. TiGenix NV TiGenix www.tigenix.com FINANCIAL SUMMARY 25 mio. EUR Cash on 30/6/2011: PROFILE COMPANY YEAR FOUNDED 2000 EMAIL [email protected] FAX +32 16 39 6050 TELEPHONE +32 16 39 6060 ADDRESS nv TiGenix Romeinse straat 12/2 B-3001 Leuven Belgium CONTACTS Eduardo Bravo Chief Executive Officer Claudia D’Augusta, Chief Finance Officer Mr Gil Beyen Chief Business Officer WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u hairman of the Board of WntResearch and clinical scientific advisor Chairman of the Board of Peter Buhl, MD, Professor of Clinical Oncology University of Copenhagen, Denmark. A/S, Targets Topo Co- Founder and CEO until 2010 of DMSc. WntResearch. Member of the Board and CEO for Bert Junno, Bert in Semiconductor Physics from the same university. Lund University and a Ph.D. in Physics from Bert Junno has a M.Sc. AB and on the Galecto Biotech AB, WntResearch AB, Energy Taurus Junno is currently serving on the boards of Cardiovax llc., advisory board of the Swedish Patent Office. WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company AktieTorget company is a public listed at the WntResearch (WNT.ST) founded in 2008. Sweden, spun out of Lund University, WntResearch is to develop novel anti-metastatic therapies for the treatment of cancer The focus and aim of patients unmet medical need. meets a large is Foxy-5 which is currentlyThe lead project being tested in The companyprojects Foxy-5 and Box-5. has two metastatic to enter and finalize phase 1 clinical trials in vivo models and is planned cancer in 2012. MANAGEMENT Member of the Board and Chief Scientific Officer Andersson, Tommy Lund University. Appointed Professor in Experimental Pathology at the Medical Faculty, WntResearch www.wntresearch.com PROFILE COMPANY YEAR FOUNDED 2008 EMAIL Bert.junno @wntresearch.com Madeleine.nydahl @wntreseach.com TELEPHONE +46 70 7772209 ADDRESS Södra Promenaden 69 211 38 Malmö CONTACTS Bert Junno CEO Member of the Board and Madeleine Nydahl WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u Xention Limited Limited Xention www.xention.com FINANCIAL SUMMARY investors The company’s £35 million over fourXention has so far raised rounds of venture capital financing. Agricole Private Crédit Life Science Partners, MVM Forbion Capital Partners, Sciences, include Seroba Kernel Life and Foresight Group. Isis Equity Partners Ventures, Albany BTG International, Ventures, Spark Equity, PROFILE COMPANY The Company is discoveryXention specialises in the development of ion channel-modulating and drugs. unmet medical need in an area of substantial drugs fordeveloping potential breakthrough atrial fibrillation (AF), which Xention has developed considerable expertise. AF is predicted to increase of physicians and the prevalence AF is the most common cardiac arrhythmia facing AF. It is estimated that are caused by between 15 and 25% of strokes two- to three-fold in the next 50 years. are expressed AF targets Kv1.5 and IKACh both of which programmes are focused on the exciting new Xention’s are thus developing atrial-specific therapeutics thatsinus rhythm to maintain normal We only in the atria. AF. prevent the recurrence of is a highly potent and selective modulator of the voltage-gated potassium XEN-D0103, lead compound, Xention’s This programme is currently in Phase 1 in vivo models. channel Kv1.5 and show excellent efficacy in pre-clinical clinical development. Xention has also developed highly modulators potent and selective of the potassium channel IKACh which are about to enter development. Xention is undertaking early-stage ion channel discovery research in other AF, In addition to its work on Grünenthal GmbH. and therapeutic fields with third-party collaborators including Ono Pharmaceutical Co Ltd. a newly established company Xention demerged its overactive bladder interests into Provesica Ltd, In late 2010, TRPV1 antagonist XEN-D0501 through Phase 2 clinical development. that will progress the MANAGEMENT Executive Management Chief Executive Ph.D., Brears Tim Chief Medical Officer FFPM, FRCA, Patrick M Round MB BS, VP programme management W Ford Ph.D., John Research VP, David J Madge PhD, Director of Finance T Hemsley, Rebecca Chairman Keith McCullagh, YEAR FOUNDED 2002 EMAIL [email protected] FAX +44 (0)1223 493901 TELEPHONE +44 (0)1223 493900 ADDRESS Xention Limited Iconix Park London Road Cambridge Pampisford, CB22 3EG United Kingdom CONTACT Brears Tim Dr Chief Executive Officer ECM SPONSORS WELCOME

Partnering Organisations

Citigate Dewe Rogerson www.citigatedr.co.uk

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and VC PARTNER corporate communications across the UK, Europe, North America and Asia. Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors. PAESPRESENTING COMPANIES SPEAKERS The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

Citigate Dewe Rogerson 3 London Wall Buildings London Wall London EC2M 5SY Tel: +44 (0)-207-638-9571 PARTNERING ORGANISATIONS t back :: next u EINLPRNR ORGANISERS REGIONAL PARTNERS WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS t back :: next u www.collegehill.com/lifesciences College Hill Life Sciences provides a full serviceCollege Hill Life Sciences communications consultancy focused on science-based life science field we haveWithin the established position a leadership our by working in partnership with sectors. communicationsclients to deliver high quality that build corporatevalue and promote leading edge products, technologies and services). London Sue Charles UK London EC3N 4QN, Royal Mint Court, The Registry, 7866 7900 +44 (0)20 +44 (0)20 7457 2020 F: T: [email protected] Email: Manchester Dr Eileen Paul / Chris Fisher UK CW12 1DN, Congleton, Way, Mountbatten Meadowside, 296501 +44 (0)1260 +44 (0)1260 296500 Fax: Tel: [email protected] Email: Munich Dr Douglas Pretsell Germany 80333 Munich, Augustenstraße 79, (0)89 52 38 80 06 +49 +49 (0)89 57 00 18 06 Fax: Tel: [email protected] Email: San Francisco Erik Clausen USA CA 94105, San Francisco Suite 1100, 201 Spear Street, +1 (415) 230 5385 Tel: [email protected] Email: College Hill Partnering Organisations Partnering Life Sciences ECM SPONSORS WELCOME

Partnering Organisations

Tiberend Strategic Advisors, Inc. www.tiberendstrategicadvisors.com VC PARTNER

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation PAESPRESENTING COMPANIES SPEAKERS 2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc. 35 W. 35th Street, 5th Floor, New York, NY 10001-2205 Tel: 212.827.0020 Fax: 212.827.0028 Fax PARTNERING ORGANISATIONS t back :: next u EINLPRNR ORGANISERS REGIONAL PARTNERS ECM SPONSORS WELCOME

Regional Partners

BioTOP Berlin-Brandenburg www.biotop.de VC PARTNER

BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region. It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster.

The services provided by BioTOP include: PRESENTING COMPANIES SPEAKERS • Technology transfer science - industry • Initiation and support of networks • Support for technology-oriented start-ups • Funding support for innovative projects • Providing information on biotechnology • Building and coordination of scientific and interdisciplinary networks • Establishing contacts between experts from all disciplines • Design and organization of events • Public relations work for the biotech region Berlin-Brandenburg

For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at www.biotop.de.

Dr. Kai Bindseil BioTOP Berlin-Brandenburg Fasanenstr. 85 PARTNERING ORGANISATIONS 10623 Berlin - Germany Tel: +49 30 318 622 11 Fax + 49 30 318 622 22 REGIONAL PARTNERS t back :: next u ORGANISERS ECM SPONSORS WELCOME

Regional Partners

Life Science Austria - LISA www.lifescienceaustria.at VC PARTNER

Life Science Austria - LISA - is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria. Working with all existing life science clusters in the Austrian regions – ecoplus, human.technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build PRESENTING COMPANIES SPEAKERS on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development. Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).

Austria Wirtschaftsservice Gesellschaft mbH Ungargasse 37 1030 Wien Austria tel.: +43 (1) 501 75 - 0 fax: +43 (1) 501 75 - 900 email: [email protected] PARTNERING ORGANISATIONS REGIONAL PARTNERS t back :: next u ORGANISERS ECM SPONSORS WELCOME

Regional Partners

SwissBiotech www.swissbiotech.org VC PARTNER

One Nation – One Biotech Cluster Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to PRESENTING COMPANIES SPEAKERS date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well- trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries: SwissBiotech Executive Office Tel. +41 (0)44 455 56 78 PARTNERING ORGANISATIONS REGIONAL PARTNERS t back ORGANISERS ECM SPONSORS WELCOME

Organisers

Sachs Associates www.sachsforum.com VC PARTNER

Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on

the practical benefi ts accruing from conference participation, the exchange of ideas and information, and the PRESENTING COMPANIES SPEAKERS facilitating of business transactions. The benefits of conference participation with Sachs Associates may be summarised as follows: Multimedia Exposure Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies, including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established relationships with other financial press organisations globally, which allow further effective distribution on behalf of its clients. Eminent Speakers Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted the very senior political and economic personalities as speakers at its events. Sponsorship and Marketing Opportunities for forthcoming events Sachs Associates has developed an extensive knowledge of the key individuals operating within the European PARTNERING ORGANISATIONS and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events. The following sponsorship and marketing opportunities are available at future conferences: • Conference Sponsor – including workshops and social events • Exhibition stands • Distribution of Promotional Material If your company is interested in exhibiting or sponsorship opportunities please call Zoe Harris on +44 203 463 4890. REGIONAL PARTNERS ORGANISERS WELCOME SPONSORS VC PARTNER SPEAKERS PRESENTING COMPANIES PARTNERING ORGANISATIONS REGIONAL PARTNERS ORGANISERS London WC1V 7QT 5th Annual 330 High Holborn 1st Floor Holborn Gate Tel: +44 203 463 4890 Tel: Fax: +44 (0)20 7405 4411 Fax: 28 – 29 February Zurich 2012 • www.sachsforum.com Biotech & Pharma Industry PARTNERING & INVESTING in PARTNERING We look forward to seeing you at: We

EUROPEAN LIFE SCIENCE CEO FORUM EUROPEAN LIFE SCIENCE M U R O F R O T S E V N I E P O R U E N I H C E T O I B